

Curriculum vitae

Name: Martin Alexander Storr
Title: Prof. Dr. med. Dr. med. habil.
Date of Birth: 11. June 1970
Born in: Munich / Germany
Nationality: German

Address: Zentrum für Endoskopie
Oßwaldstr. 1
82319 Starnberg
Tel: 08151-971096
Fax: 03212-1027208

Present rank: Associate Professor (apl. Prof.), Consultant
Position: Consultant Gastroenterology
Head, Laboratory of Neurogastroenterology
Institution: Center of Endoscopy, Starnberg
Ludwig-Maximilians University, Munich, Germany



Academic background:

Final degree: MD, Specialist in Internal Medicine, Gastroenterology and Proctology
MHBA, Master of Health Business Administration

Undergraduate

- Preclinic studies of Medicine at the University of Regensburg, Germany, 1990 – 1991
- Elective Period Holy Cross Hospital, Detroit, MI, USA July-Sept, 1991
- Preclinic studies of Medicine at the University of Saarland, Germany, 1989 – 1990

Graduate and post-doctoral

- MHBA, Friedrich Alexander University Nürnberg, Germany 2014
- 2nd State-exam for Medicine at the Technical University of Munich, Germany, 1996
- 1st State-exam for Medicine at the Technical University of Munich, Germany, 1995
- Clinical study of Medicine at the Technical University of Munich, Germany, 1993 – 1996
- Clinical study of Medicine at the University of Vienna / Austria, 1992 – 1993
- Clinical study of Medicine at the Technical University of Munich, Germany, 1991 – 1992

Licensure, Certifications and Boards

- Consultant Gastroenterology, Center of Endoscopy, 2015
- Full licence as specialist in Proctology, 2013
- Consultant (Funktionsoberarzt) Endoscopy, at the Ludwig-Maximilians University Munich, 2013
- Associate Professor (Außerplanmässiger Professor (*apl. Prof.*)) at the Ludwig-Maximilians University Munich, January 2012
- Consultant (Funktionsoberarzt) Gastroenterology, at the Ludwig-Maximilians University Munich, 2011
- Adjunct Associate Professor, Division of Gastroenterology, Department of Medicine, University of Calgary, 2011
- Full licence as specialist in Gastroenterology, July 2006
- Venia legendi in Medicine at the Ludwig-Maximilians University Munich, April 2005

- Habilitation in Internal Medicine (PD Dr. med. habil.) with a thesis in Gastroenterology: New approaches to therapeutic modulation of gastrointestinal neurotransmission and motility, April 2005
- Full licence as a specialist in Internal Medicine, October 2003
- Full - Approbation as Medical Doctor, January 1998
- Doctor of Medizin (Dr. med.) with a thesis in Gastroenterology at the Technical University of Munich „Inhibitorische Mechanismen am Ileum der Ratte – Zelluläre Wirkungsweisen von Neurotensin, ATP, SIN-1 and c-GMP“, magna cum laude, 1997
- Full Member of the Bavarian Landesärztekammer (BLÄK), May 1996
- Full Member of the German Bundesärztekammer (BÄK), May 1996
- Partial - Approbation as Medical Doctor, May 1996

Additional Qualifications

- Certificate Neurogastroenterology DGVS), 2014
- DRG-Training Munich, 2013
- Renewal permit to use diagnostic X-Ray (Fachkunde Strahlenschutz) 2012
- BWL im Krankenhaus, cekib-Klinikum Nürnberg (Nov 2011-Nov 2012)
- Certificate Gastrointestinal Oncology (DGVS), 2011/2
- Gastrointestinal Endosonography (EUS-workshop), Wiesbaden, September 2011
- Peroral Endoscopic Myotomy (POEM) workshop, Hamburg, August 2011
- Endoscopic Submucosal Dissection (ESD) workshop, Garmisch-Partenkirchen, July 2011
- Canadian Medical Association (CMA), Physician Management Institute (PMI) Course: Leadership and Professional Development – Engaging others, Vancouver, 2010
- MECUM Teaching (Harvard Medical International-LMU), 2004
- Clinical trials following AMG, 2004
- Theaterarzt, Konzertarzt seit 2003
- Speakers Training; Lehren und Lernen an der TU München, 2003
- Permit to use diagnostic X-Ray (Fachkunde Strahlenschutz) 2003
- Diagnostic ultrasound use in Internal Medicine, 2001
- Clinical trials following AMG, 1999
- Accreditation for Emergency Medical Services (EMS, Fachkunde Rettungsdienst), 1999

Appointments - present:

- 02/2015 – present: Chairman, German Society of Neurogastroenterology and Motility
- 01/2015 – present: Consultant Center of Endoscopy, Starnberg and Center of Internal Medicine, Gauting, Germany
- 04/2011 – present: Adjunct Associate Professor, University of Calgary, Canada, Department of Medicine, Division of Gastroenterology

Appointments - past:

- 04/2011 – 12/2014: Associate Professor, Department of Internal Medicine II – Division of Gastroenterology of the Ludwig Maximilians University Munich
- 09/2010 – 03/2011: Member of the Calgary Institute for Population and Public Health, University of Calgary, Canada, Faculty of Medicine
- 07/2007 – 03/2011: Member of the Calvin, Phoebe & Joan Snyder Institute of Infection, Immunity & Inflammation, University of Calgary, Canada, Faculty of Medicine
- 07/2007 – 03/2011: Associate Professor, University of Calgary, Canada, Department of Medicine, Division of Gastroenterology
- 07/2008 – 03/2009: Director of Graduate Education Research (GEC), University of Calgary
- 07/2006 – 03/2011: Member of the Gastrointestinal Research Group (GIRG), University of Calgary, Canada, Faculty of Medicine
- 07/2006 – 06/2007: Visiting Professor at the University Calgary, Department of Physiology and Biophysics, Canada
- 04/2005 – 06/2006: Associate Professor, Department of Internal Medicine II – Division of Gastroenterology of the Ludwig Maximilians University Munich
- 01/2004 – 04/2005: Assistant Professor at the Department of Internal Medicine II – Division of Gastroenterology of the Ludwig Maximilians University Munich (Director: Prof. Dr. B. Göke)
- 01/1998 – 12/2003: Assistant Professor at the Department of Internal Medicine II of the Technical University Munich (Director: Prof. Dr. Dr h.c. mult M. Classen; since 1. Oct 2002 Prof. Dr. R.M. Schmid)
- 07/1996 – 12/1997: Resident of the Department of Internal Medicine II of the Technical University Munich (Prof. Dr. Dr. h.c. mult. M. Classen)

Awards and Distinctions:

Major Awards and Distinctions

- Neurogastroenterology Award, Stiftung für Neurogastroenterologie, Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) 2011
- International Foundation for Functional Gastrointestinal Disorders (IFFGD) Junior Investigator-Basic Science Award, 2009
- URGC Research Grant Award (University of Calgary Research Grant Committee) 2008
- Invitation list for Head of Department of Physiology, University of Vienna, Austria, June 2008
- CCCF Visiting Scientist Award (Canadian Crohn's and Colitis Foundation) 2006
- AHFMR Visiting Scientist Award (Alberta Heritage Foundation for Medical Research) 2006
- Best MD Thesis Award (Supervisor), Ludwig Maximilians University 2005
- Werner Creutzfeld Award for Gastrointestinal Physiology, German Society of Digestive Diseases (DGVS) 2005
- University of Munich (FöFoLe) Research Grant Award, 2004

Poster Awards and other Distinctions

- Poster of Distinction UEGW, Berlin, October, 2013
- Poster of Distinction DDW, Orlando, USA, May, 2013
- UCME Distinguished Service Teaching Award 2010/2011
- URGC Lecturer Travel Award, 2009
- Poster of Distinction DDW Chicago, IL, 2009
- Poster of Distinction Neurogastroenterology and Motility 2008 Joint International Meeting, Lucerne, Ch, 2008
- Poster of Distinction DDW San Diego, California May 2008
- Poster of Distinction DDW Washington, USA, May 2007
- Poster of Distinction of the Mitteldeutsche Gesellschaft für Gastroenterologie 2005
- Travel Award of the Dt. Gesellschaft für Neurogastroenterologie und Motilität 2003
- Poster Award of the Gesellschaft für Gastroenterologie in Bayern, 2000
- Travel Award of the Gesellschaft für Gastroenterologie in Bayern, 2002
- Travel grant of the DAAD (Deutscher Akademischer Austauschdienst) 1992

Awards and other Distinctions to Trainees

- Conference Support Award from the Canadian Consortium for the Investigation of Cannabinoids) to Mohammad Bashahshati, 2012
- Travel Award ICRS (International Cannabinoid Research Society) to Mohammad Bashahshati, 2012
- Best CDDW-GRIT Presentation Award to Edwin Cheng MD CDDW 2012
- GIRG Shaffer Award 2011 for best clinical presentation runner-up Mike Stewart MD
- Junior Basic Scientist Award of the Austrian Pain Society 2011 to Rudolf Schicho PhD
- Iuventus Plus Award (Polish Ministry of Science and Higher Education; for: Pharmacological characterization of salvinorin A and its synthetic analogs as potential novel therapeutics for the treatment of GI inflammation and functional disorders) 2010 to Jakub Fichna PhD
- UEGF and ASNEMGE National Scholar Award 2010 to Jakub Fichna PhD
- UEGW and Conference Travel Award 2010 to Jakub Fichna PhD
- Trainee Conference Support Award from the Canadian Consortium for the Investigation of Cannabinoids, 2010, to Mohammad Bashashati MD
- Travel Award of the Joint International Meeting in Neurogastroenterology and Motility in Boston, 2010, to Mohammad Bashashati MD
- Poster of Distinction CDDW 2010
- GIRG Shaffer Award 2010 for best clinical presentation to Atyab Syeed MD
- Werner Creutzfeld Best MD Thesis Award 2005 to Birol Yuce MD

Professional Activities:

Memberships

- European Society for Neurogastroenterology and Motility (ESNM)
- Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS)
- Deutsche Gesellschaft für Neurogastroenterologie und Motilität (DGNM)
- Arbeitskreis Gastrointestinale Physiologie (GAP)
- International Group for the Study of Neurogastroenterology & Motility (IGSNM)
- International Foundation for Functional Gastrointestinal Disorders (IFFGD)
- Gesellschaft für Gastroenterologie in Bayern (GFGB)
- Belgian Network on Gastrointestinal Regulatory Mechanisms (GIREM)
- History of Neuroscience Interest Group (HONIG)
- IBD Research Institute of the CCFC (IBDRI)
- Canadian Consortium for the Investigation of Cannabinoids (CCIC)
- Cochrane Collaboration, Inflammatory Bowel Disease and Functional Bowel Disorders Group
- European Microscopic colitis Group (EMCG)
- Deutsche Eosinophile Ösophagitis Gruppe (DEOS)

Editor

- Gastro News (Springer) (2017 – ongoing)

Associate Editor

- Medizinische Monatsschrift für Pharmazeuten (MMP)
- Münchner Medizinische Wochenschrift (MMW)
- BMC Gastroenterology (2008-2012)
- Frontiers in Gastrointestinal Pharmacology (2010-ongoing)
- Journal of Gastrointestinal & Digestive System (OMICS; 2010 – ongoing)
- Canadian Journal of Gastroenterology (2016 – ongoing)

Supplement Editor

- Canadian Journal of Gastroenterology

Reviewer for scientific journals

- Alimentary Pharmacology & Therapeutics
- American Journal of Gastroenterology
- American Journal of Physiology – Gastrointestinal and Liver Physiology
- ACS Chemicals Neuroscience
- Archives of Medical Research
- Arab Journal of Gastroenterology
- Biochimie
- British Journal of Pharmacology
- BMC Gastroenterology
- Clinical Gastroenterology & Hepatology
- Clinical and Experimental Pharmacology & Physiology
- Canadian Journal of Gastroenterology
- Canadian Journal of Physiology & Pharmacology
- Clinical Pharmacology & Therapeutics
- Contemporary Clinical Trials
- Digestion
- Digestive Diseases and Sciences
- Digestive and Liver Disease
- Drug Discovery Today
- Drugs
- European Journal of Gastroenterology & Hepatology
- European Journal of Pharmaceutical Sciences
- Experimental and Molecular Medicine
- Expert Opinion On Drug Metabolism & Toxicology
- Expert Opinion on Investigational Drugs
- Expert Opinion on Pharmacotherapy
- Expert Opinion on Therapeutic Patents
- Expert Review of Gastroenterology and Hepatology
- Gastroenterology
- Gastroenterology Research and Practice
- GUT

- International Journal of Medicine
- Journal of Clinical Gastroenterology
- Journal of Crohn's & Colitis
- Journal of Gastroenterology & Hepatology
- Journal of Molecular Medicine
- Journal of Proteome Research
- Journal of Postgraduate Medicine
- Life Sciences
- Mucosal Immunology
- Nature Clinical Practice Gastroenterology and Hepatology
- Naunyn-Schmiedeberg's Archives of Pharmacology
- Nature Reviews Gastroenterology & Hepatology
- Neurogastroenterology & Motility
- Neuropharmacology
- Neuroscience
- Neuroscience Letters
- Pharmacological Research
- Phytotherapy Research
- The Open Bioactive Compounds Journal
- Therapeutics and Clinical Risk Management
- World Journal of Gastroenterology
- Yonsei Medical Journal
- Zeitschrift für Gastroenterologie

Local/National/International Committee Service/Funding Agencies

- Health Research Board, Ireland, 2013
- Natural Sciences and Engineering Research Council of Canada (NSERC), 2012
- DGVS (Deutsche Gesellschaft für Verdauungs und Stoffwechselkrankheiten)
Preiskomitee Vortragspreis Basic Science Sept 2012.
- Reviewer for Research grants Deutsche Forschungsgesellschaft (DFG) since 2012
(Area Neurogastroenterology – Drug Development)

- Evaluator for the IDEAS research program (Romanian National Council for Scientific Research) since 2011
- Reviewer for the Michael Smith Foundation for Health Research (MSFHR), 2011
- Reviewer ANMS Meeting 2011 St Louis Sep16-18. Neuroimmune Modulation and Neural Control of Secretomotor, Vasomotor, Barrier and Other Gut Functions in Health and Disease Board member of the Leaders in Medicine Programme at the University of Calgary, 2010
- Reviewer and Chair American Gastroenterological Association (AGA) Section: Constipation: Diagnosis and Treatment, 2011
- Reviewer Neurogastroenterology and Motility Joint International Meeting. Brain gut axis: Animal studies, 2009
- Reviewer for Research grants Fund for Scientific Research (FWO), Belgium, 2008, 2009, 2011, 2012
- Reviewer for Research grants German-Israeli-Foundation 2007
- Reviewer and Chair American Gastroenterological Association (AGA) Meeting Section: Motility & Nerve-Gut interactions – Pharmacotherapeutics in Functional Gastrointestinal Motility Disorders 2007, 2008, 2009
- Reviewer for Research grants Gesellschaft zur Förderung von Forschung und Lehre der Ludwig-Maximilians Universität München 2006, 2007
- Reviewer for Research grants Broad Medical Research Program - Inflammatory Bowel Disease Grants - The Eli and Edythe L. Broad Foundation, 2006
- Reviewer and co-Chair Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) Meeting Abstracts: Neurogastroenterologie & Motilität 2003, 2004, 2005, 2006

Board Member

- 09/2012 – present OA-Gastroenterology / online publishing
- 06/2012 – present Advisory Board Almirall (Linaclotide)
- 08/2011 – ongoing Medizinische Monatsschrift für Pharmazeuten, regular commentator
- 03/2011 – 06/2012 Alberta Health Services – Procurement Committee
- 11/2010 - present Advisory Board Janssen Pharm. Inc/ Johnson & Johnson Pharmaceuticals (Prucalopride)

- 10/2010 – present Advisory Board Gingco Corporate Communication GmbH / BKK-Audi Journal
- 10/2008-10/2010 Advisory Board Neurim Pharm. (Neu-P11 / Neu-P12 / Neu-P67)
- 07/2008 – 07/12: Advisory Board of the German Academic International Network (GAIN)
- 01/2008 – 03/2011 Board member of the Center of Digestive Motility (CDM), University of Calgary, Canada, Faculty of Medicine
- 06/2005 – 04/2006 Advisory Board Sanofi-Synthelabo (Rimonabant)
- 06/1996 – 05/2006: Advisory Board of UNI-MED Publishing

Principal or Co-investigator in investigator initiated clinical trials (IIT) following Good Clinical Practice (GCP)

- The Effect of Piromelatine on Symptoms in Patients with D-IBS, 2011-ongoing (PI)
- Metabolomic and other biomarker analysis, potential tools to direct treatment with biologicals in IBD The MARKER-Study. 2010-ongoing (PI)
- Metabolomic analysis in patients with inflammatory bowel disease (IBD), 2009-2012 (PI)
- A novel method of full-thickness gastric biopsy via a percutaneous, endoscopically assisted, transenteric approach. 2009-2011 (coI)
- Prospective Assessment of BRAVO pH testing using a transoral approach. 2008-2010 (coI)
- Treatment of patients with Crohn's disease with oral cannabis sativa extract – a randomized, placebo-controlled double blind study. 2005-2007(PI)
- Treatment of patients with diffuse esophageal spasm with botulinum toxin – a randomized, placebo-controlled double blind study. 2003-2006 (PI)
- Comparison of botulinum toxin and balloon dilatation treatment in patients with Achalasia. 1998-2001 (coI)

Participation in clinical studies following Good Clinical Practice (GCP)

- A 12-week double-blind, randomised, placebo-controlled, parallel-group phase III study, followed by a 4-week randomised withdrawal period to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in female patients with irritable bowel syndrome with diarrhoea (IBS-D). Study Code: NAK-06; Study Acronym: IRIS-3: Ibodutant for Relief of Irritable Bowel Syndrome. Menari Ricerche, ICON, 2013-ongoing

- A randomized phase III, double-blinded, active controlled study of CB-183,315 in patients with clostridium difficile associated diarrhea, Cubist Pharmaceuticals, 2013-ongoing
- A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 26 Weeks (Echo 1), Pharmaceutical Research Associates GmbH , Ferring, 2013-ongoing
- A Multicenter, Open-label Safety and Tolerability Extension Trial of Elobixibat 5 mg and 10 mg Daily in the Treatment of Chronic Idiopathic Constipation (Echo 3), Pharmaceutical Research Associates GmbH , Ferring, 2013- ongoing
- Double-blind, double-dummy, randomized, placebo-controlled, phase IIa study on the efficacy and tolerability of a 14-day treatment with budesonide effervescent tablets vs. viscous budesonide suspension vs. placebo in patients with eosinophilic esophagitis. Aptiv Solutions, Dr. Falk Pharma, 2012-2013
- A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects with Gastroparesis. GlaxoSmithKline. 2009-2011
- Multicenter, Randomized, Placebo-controlled, Doubleblinded Study of the Efficacy and Safety of Lubiprostone in Patients with Opioidinduced Bowel Dysfunction. Sucampo Pharmaceuticals, Inc. 2007-2009
- Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose, Dose Escalation Study to Evaluate the Efficacy, Safety and Tolerability of NKTR-118 in Patients with Opioid-induced Constipation (OIC.) Nektar Therapeutics 2007-2009
- Efficacy and safety study of oral administration of SR48968C, NK2 antagonist, in patients suffering from Irritable Bowel Syndrome (IBS). A multicentric, double-blind, placebo-controlled dose ranging (Phase IIB) study. 2003
- Evaluation of the ENDONETHICS Gatekeeper Systems in the treatment of gastroesophageal reflux disease. 2002-2003
- Open Study of Synercid (quinupristin/dalfopristin RP 59500) for emergency use (Infections due to resistant bacteria, treatment failure or in treatment – intolerant patients). 2001-2003
- Prospektive, randomised, doubleblind, multicenter (Phase IIIb) study to compare the efficacy and tolerance of Piperacillin/Tazobactam vs. Imipenem/Cilastatin in the treatment of hospitalized patients with nosocomial pneumonia. 2001-2003

- Clinical trial of the efficacy of the somatostatinanalogon - Lanreotide – as an adjuvans to endoscopic treatment in patients with acute bleeding from esophageal varices resulting from liver cirrhosis and portal hypertension. 2000-2002

Member, Guidelines/Recommendations

- Performance and interpretation of esophageal manometry: recommendations of the German Societies for Neurogastroenterology and Motility (DGNM), for Digestive and Metabolic Diseases (DGVS) and for General and Visceral Surgery (DGAV)

Keller, J., Fox, M., Nicolaus, M., Schirra, J. Van der Vort, I., Fox, M., **Storr, M.:** Performance and Interpretation of Esophageal Manometry: Recommendations of the German Societies for Neurogastroenterology and Motility (DGNM), for Digestive and Metabolic Diseases (DGVS) and for General and Visceral Surgery (DGAV)., ZFG, 47(9):830-845, 2009 (IP 0.9)

- Clinically relevant breath tests in gastroenterological diagnostics--recommendations of the German Society for Neurogastroenterology and Motility as well as the German Society for Digestive and Metabolic Diseases

Keller, J., Franke, A., **Storr, M.**, Wiedbrauck, F., Schirra, J.: Klinisch relevante Atemtests in der gastroenterologischen Diagnostik. Empfehlungen der Deutschen Gesellschaft für Neurogastroenterologie und Motilität sowie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten. Zeitschrift für Gastroenterologie, 43, 1171-1190, 2005 (IP 1.3)

Team Leader: The Cochrane Library Systematic Review: Prucalopride for the treatment of chronic constipation (Rev 141)

Rezaie A, Cheng EJ, Jijon HB, Kumar S, **Storr M.** Prucalopride for the treatment of chronic constipation.

<http://summaries.cochrane.org/CD009636/prucalopride-for-the-treatment-of-chronic-constipation>, 15.2.2012 (IP 5.7)

Team Leader: The Cochrane Library Systematic Review: Interventions for promotion of mucosal healing in Crohn's disease (Rev 142)

Team Member: The Cochrane Library Systematic Review: Interventions for induction of mucosal healing in ulcerative colitis (Rev 144)

Team Member: The Cochrane Library Systematic Review: Interventions for maintenance of mucosal healing in ulcerative colitis_(Rev 145)

Educational Activities:

Invited Presentations

1. Neue therapeutische Optionen beim Reizdamsyndrom. QZ des Ärztlichen KV Berchtesgaden , 10.3.2014
2. Reizdarm im Fokus, 1. Augsburger Ärzte Update, 15. 2. 2014
3. Gastrointestinale Blutung, Fortbildungskolloquium der Med klinik 3, Grosshadern, 28.01.2014
4. The Endocannabinoidsystem in the Gastrointestinal tract. Tongji University, Shanghai, China, 2.12.2013
5. IBD Ahead, Reizdarm und CED, Pathophysiologie und Diagnostik, München, 23.10.2013
6. IBD Ahead, Reizdarm und CED, Therapie, München, 22.10.2013
7. Leitliniengerechte Therapie der Reizdarmerkrankung, Jahrestagung der Bayerischen Internisten, München, 18.10.2013
8. Pathologische Befunde im Duodenum, GATE, München 09.10.2013
9. Neues zu Pathyphysiologie und Therapie der Reizdarmerkrankung, Qualitätszirkel Dachau, 25.9.2013
10. Update Gastrointestinale Blutung, Medizinische Klinik III, LMU München, 30.7.2013
11. Gastrohighlights - DDW 2013; Reizdarm-Update, Nürnberg, 24.6.2013
12. Gastrohighlights - DDW 2013; Reizdarm-Update, München, 17.6.2013
13. Therapiestrategien bei Reizdarmerkrankung – Reizdarm Update, München, 17.6.2013
14. Reizdarmsyndrom- Pathophysiologie und Wirkmechanismen, Stuttgart, 19.5.2013
15. Gastrointestinale Störungen bei autonomer diabetischer Neuropathie, Thüringer Diabetesgesellschaft, Weimar, 16.3.2013
16. Mikroskopische Kolitis – Update 2013, Universitätsklinik Magdeburg, 19.2.2013
17. Reizdarm – Rationelle Diagnostik – Sinnvolle Therapie. 20. Praxisseminar des St. Theresien Krankenhauses Nürnberg. 8.2.2013
18. CED und Reizdarm, gibt es das? 7. Arzt-Patienten Seminar CED, Memmingen 24.11.2012
19. Aktuelle und zukünftige Wirkmechanismen bei der Reizdarmtherapie. Symposium im Rahmen der GfGB Bamberg 18.10.2012
20. Therapiestrategien bei Reizdarmsyndrom, im Rahmen des Reizdarm-Update 2012 Effiziente Diagnostik und rationaler Einsatz neuer Therapiestrategien. 10. 10. 2012, München
21. Achalasie und mehr – Ösophageale Funktionsdiagnostik, Update gastroenterologische Funktionsdiagnostik im Rahmen der 67. Jahrestagung der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS). 20.9.2012 Hamburg
22. Reizdarmsyndrom, Therapeutische Möglichkeiten und Wirkmechanismen, Symposium Neue Horizonte in der Reizdarmtherapie im Rahmen der 67. Jahrestagung der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS). 20.9.2012 Hamburg
23. Microscopic Colitis – Role of Diet, Life Style and Drugs. EAGEN Postgraduate Course, 29.June 2012, Treviso, Italy
24. Endoskopische Pathologien im Duodenum. GATE – Endoskopiekurs, München, 06.10.2011
25. Future of cannabinoid drugs in the treatment of FGD, 9th IFFGD Symposium, 8-10 April 2011, Milwaukee, USA
26. Motility disorders of the upper GI tract, 35th Annual Family Practice Review and Update, Calgary, Canada, 15.11.2010
27. Gut Sensation & Visceral Pain, UME Course 1, Calgary, Canada, 22.09.2010

28. Irritable Bowel Syndrome. An Update. FAMS-Course, Calgary, Canada, 11.06.2010
29. Workshop: "Doctor, my bowels have become irregular..." FAMS-Course, Calgary, Canada, 11.06.2010
30. Non cardiac chest pain. Division of Gastroenterology Grand Rounds, 12.3.2010, Calgary, Canada
31. Cannabinoid regulation of gut functions: from bench to bedside. Canadian Digestive Disease Week (CDDW) 27.02.2010, Toronto, Canada
32. SIBO – Small Intestinal Bacterial Overgrowth. Division of Gastroenterology, 27.1.2010, Calgary, Canada
33. Diagnostic tools in functional gastrointestinal disorders. RGH CME-Rounds. 11.12.2009, Calgary, Canada
34. Human ENS as a Target for Drug Therapy – The Endocannabinoid System in Motor and Inflammatory Disorders. International Society of Neurogastroenterology and Motility. 28.08.2009, Chicago, USA
35. New approaches in diagnosis and treatment of GERD. Updates in Gastroenterology. 07.02.2009, Lake Louise, Canada
36. GERD, Dysphagia, Non-cardiac chest pain (NCCP) and Barretts. A journey through the GUT, Calgary, May 3rd 2008.
37. Functional disorders of the esophagus - Non cardiac chest pain (NCCP) and Dysphagia. Foothills Medical Centre – Medical Grand Rounds – 22.April 2008
38. Refractory Dyspepsia Management - Treatment of Functional Dyspepsia (FD) refractory to proton pump inhibitors, 25th Annual Calgary Therapeutics Conference 4.4.2008
39. GERD – Novelties in diagnostics and therapy. Advances in Gastroenterology. 24.11.2007, Lake Louise, Canada
40. The role of the enteric nervous system (ENS) in inflammatory bowel disease (IBS). 6th Annual Western Canada IBD Symposium. 18.11.2007, Banff, Canada
41. Is the gut an addict? GIRG (Gastrointestinal Research Group) Retreat. 29.01.2007, Kananaskis, Canada.
42. Cannabinoids in gastrointestinal inflammation and motility. GIRG Seminar Series, 17.10.2007, Calgary, Canada
43. Digestion & Absorption. UME GI-Course University of Calgary. 03.10.2007, Calgary, Canada
44. Esophageal Motility Disorders: Diagnosis and Treatment. Divisional evening lecture 28.02.2007, Calgary, Canada
45. Was ist notwendig, was ist entbehrlich in der Diagnostik der Gastroösophagealen Refluxerkrankung? Deutsche Gesellschaft für Endoskopie und Bildgebende Verfahren, 23. März 2006, München
46. Obere Gastrointestinale Blutung. Deutsche Gesellschaft für Endoskopie-Assistenzpersonal. Deutsche Gesellschaft für Endoskopie und Bildgebende Verfahren, 23. März 2006, München
47. Welche besonderen Untersuchungen gibt es bei Beschwerden im Bereich der Speiseröhre. 5. Eichstätter Gesundheitsgespräch. 11.03.2006, Eichstätt
48. Endoskopische Pathologien im Duodenum. GATE – Endoskopiekurs, München, 26.04.2006
49. Das Rio Studienprogramm. Rimonabant Experten Workshop. 8.4.2006, München
50. Pankreasfunktionsdiagnostik – Was ist sinnvoll? Symposium Pankreasdiagnostik. 5.4.2006, München
51. Das Endocannabinoid-System und seine direkten Wirkungen. Forum Kardiometabolisches Risikomanagement. 9.9.2006, München
52. Das Rio Studienprogramm. Rimonabant Experten Workshop. 16.9.2006, Stuttgart

53. Ein Patient mit nicht kardialen Thoraxschmerz und Dysphagie. Klinikskonferenz der Medizinischen Kliniken in Großhadern, 24.01.2005
54. Neues in Diagnostik und Therapie der Gastroösophagealen Refluxerkrankung. Symposium – Erkrankungen des gastro-ösophagealen Übergangs, Klinikum Dachau, 16.02.2005
55. Motilitätsstörungen des Gastrointestinaltraktes. Was ist wichtig in Diagnostik und Therapie? Gastroenterologisches Forum des Krankenhauses Bad Oeynhausen, 16.03.2005, Bad Oeynhausen
56. Neue Methoden in der Diagnostik der gastroösophagealen Refluxerkrankung. Fakultätskolloquium, 27.4.2005
57. Motilitätsstörungen bei Diabetes mellitus. Interdisziplinärer Fortbildungsnachmittag der Medizinischen Klinik II und der Chirurgischen Klinik im Klinikum der Ludwig-Maximilians-Universität München, 11.05.2004, München
58. Funktionelle Erkrankungen des Gastrointestinaltraktes. Jahrestagung der Deutschen Flugmediziner, 18.6.2005, Fürstenfeldbruck
59. Gastroösophageale Refluxerkrankung. Weiter so oder brauchen wir Neuwahlen? Antrittsvorlesung an der LMU München, 15.07.2005, München
60. Endoskopische Pathologien im Duodenum. GATE – Endoskopiekurs, München, 5.10.2005
61. Evidenz-basierte Phytotherapie bei funktioneller Dyspepsie: Eine systematische Analyse der klinischen Evidenz zu Iberogast. Phytopharmaka und Phytotherapie 7.10.2005, Berlin
62. Physiologie und Pathophysiologie des Anorektalkanals. Kurs Funktionsdiagnostik des Anorektums, 22.11.2005, München
63. Manometrie des Ösophagus: Wie und Wann? Interdisziplinärer Fortbildungsnachmittag der Medizinischen Klinik II und der Chirurgischen Klinik im Klinikum der Ludwig-Maximilians-Universität München. 09.11.2004, München
64. Elektrophysiologische Charakterisierung des Einflusses von Cannabinoidrezeptoren bei der Neurotransmission im Rahmen der intestinalen Peristaltik. Gesellschaft zur Förderung von Forschung und Lehre 11.11.2005 München
65. C13-HP-Atemtest zum Nachweis von Helicobacter pylori. Gastroenterologische Funktionsdiagnostik, 18.11.2005, Aschaffenburg
66. Alternative CED Therapien. 4. Münchner Symposium über chronisch entzündliche Darmerkrankungen. 25.11. 2005, München
67. Fallstricke bei der Auswertung der Ösophagusmanometrie. Gastro-Forum München, 10.-11.12.2005, München
68. Die Impedanzmessung in der Ösophagusdiagnostik. Gastro-Forum München, 10.-11.12.2005, München
69. Die Rolle des Cannabinoid-1 Rezeptors im Zusammenhang mit intestinaler Inflammation. Werner-Creutzfeld Stipendiatenseminar, 15.12.2005, Berlin
70. Motilitätsstörungen bei Diabetes Mellitus – Diagnostik und Therapie. 39. Jahrestagung der Deutschen Diabetes Gesellschaft (DDG), Hannover 20.5.2004
71. Untersuchungen der Neurotransmission im Gastrointestinaltrakt von Nagetieren. Institut für theoretische Chirurgie, 17.6.2004
72. Mit STW 5 (Iberogast®) “slow-waves” modulieren. Expertengespräch: Umdenken in der Gastroenterologie – Multi-Target-Therapie: Zukunftsweisend bei funktioneller Dyspepsie. Akademie Schloss Hohenkammer, Freising, 18.6.2004
73. Update 2004 - Diagnostik und Therapie von Motilitätsstörungen – Ösophagus. 59. Jahrestagung der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten, Leipzig 3.09.2004

74. Verträglichkeit und Wirkung von standardisiertem Cannabis-Extrakt bei Patienten mit aktivem Morbus Crohn. 59. Jahrestagung der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten, Leipzig 1.09.2004
75. Endoskopische Pathologien im Duodenum. GATE – Endoskopiekurs, München, 6.10.2004
76. Cannabinoide im enterischen Nervensystem – Implikationen für den Menschen. Wissenschaftlicher Retreat der II. Med. Klinik der LMU-München 17.11.2004
77. Non-cardiac-chest-pain - Funktionelle Störungen im Gastrointestinaltrakt. Interdisziplinärer Fortbildungsnachmittag der Medizinischen Klinik II und der Chirurgischen Klinik im Klinikum der Ludwig-Maximilians-Universität München, 24.11.2004, München
78. Cannabinoide als neue Ansätze für eine therapeutische Modulation gastrointestinaler Neurotransmission und Motilität. Fakultätskolloquium der Ludwig-Maximilians Universität München, 29.11.2004, München
79. Fallstricke bei der Auswertung der Ösophagusmanometrie. Gastro-Forum München, 11.-12.12.2004, München
80. 24 Stunden pH-Metrie und Manometrie im klinischen Einsatz. Klinische Fortbildung für Pflegepersonal der II Med. Klinik der TU-München, 5. August 2003
81. Motilitätsstörungen der Speiseröhre als Differenzialdiagnose zu kardiologischen Krankheitsbildern. Klinische Fortbildungsveranstaltung der I. Med. Klinik, der TU München. 2003
82. Gastroforum München. 13.-14. 12.2002, München: Manometrikurs mit praktischen Übungen
83. Achalasie und Ösophagusspasmus: Medikamentöse Therapie, dilatieren oder Botulinum-Toxin? Diagnostik und Therapie von Erkrankungen der Speiseröhre. 17. März, Göttingen, 2001
84. Münchner Refluxstag, 22.6.2001, München: Manometrie und pH-Metrie Kurs
85. Hascht der Darm? Wissenschaftliches Kolloquium der II. Medizinischen Klinik der TU München, 12.7.2001
86. Der kranke Ösophagus – Motilitätsstörungen der Speiseröhre. Jena, September 2001
87. 9. Münchener Kurs „Gastroenterologie und Endoskopie“. 7.-8.12.2001, München: Manometrie und pH-Metrie Kurs
88. Botulinum Toxin (BTX) Injektionen in der Behandlung des symptomatischen Diffusen Ösophagusspasmus. XXX Kongreß der Deutschen Gesellschaft für Endoskopie und bildgebende Verfahren 23.-25. März, Hamburg, 2000
89. Münchener Kurs „Gastroenterologie und Endoskopie“. 6.-7.12.2000, München: Manometrie und pH-Metrie Kurs
90. Pharmacological treatment of esophageal dysfunction. European study group for dysphagia and globus; E.G.D.G., Wien, Österreich, Oktober 1998
91. Hereditäre Pankreatitis, Mutation im kationischen Trypsinogen-Gen. Klinische Fortbildungsveranstaltung der II. Med. Klinik, der TU München. 1997
92. Toxisches Megacolon als Komplikation einer Kolitis ulzerosa. Klinische Fortbildungsveranstaltung der II. Med. Klinik, der TU München. 1997
93. Diffuse follikuläre lymphatische Hyperplasie des Gastrointestinaltraktes. Klinische Fortbildungsveranstaltung der II. Med. Klinik, der TU München. 1996

Oral Presentations at Conferences

1. Charakterisierung und physiologische Wirkung eines neu-entwickelten löslichen Amylin Analogons *in vitro*, *DGVS 2013 in Nürnberg*.
2. The prokinetic drug prucalopride - First year experiences. DDW, 19.5.2012, San Diego, USA.

3. Iberogast und seine einzelnen Bestandteile beeinflussen den peristaltischen Reflex am Dünndarm der Ratte. Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V., 4. März, Hohenkammer, 2006
4. STW 5 (Iberogast®) und seine Einzelextrakte modulieren Amplitude und Frequenz der "slow-waves" am Dünndarm. Gemeinsames Symposium der Deutschen Gesellschaft für Klinische Pharmakologie und Therapie (IX. Symposium), der Gesellschaft für Phytotherapie (14. Kongress) und der Gesellschaft für Arzneipflanzenforschung, Berlin, 26.-28. Februar 2004
5. Der CB1 Cannabinoid Rezeptor moduliert die Neurotransmission im Kolon der Maus: Untersuchungen an wildtyp und CB1^{-/-} Mäusen.. Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V., 23.-25. Februar, Tutzing, 2003
6. Comparative study of different gap junction blockers on neuromuscular interaction of murine colonic smooth muscle. Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V., 23.-25. Februar, Tutzing, 2003
7. Excitatory cholinergic and inhibitory non-adrenergic, non-cholinergic neurotransmission in murine colon is modulated by the CB1 cannabinoid receptor. Intracellular recording in wild-type and CB1-deficient mice. DDW, 21. Mai, Orlando/USA, 2003
8. Der CB1 Cannabinoidrezeptor moduliert die Neurotransmission im Mäusekolon. Intrazelluläre Aufzeichnungen in Wildtyp und CB1-defizienten Mäusen. 57. Tagung der DGVS, 11. - 14. September 2002, Bonn
9. Modulatory role of nociceptin/orphanin FQ and the ORL-1 receptor on cholinergic neurotransmission and the myenteric reflex in rat ileum. XI. Eur. Symposium on Neurogastroenterology and Motility, 2. - 6. Oktober 2002, Tübingen
10. CB1 cannabinoidrezeptor modulates neurotransmission in mice colon: Intracellular recording in wild-type and CB1-deficient mice. XI. Eur. Symposium on Neurogastroenterology and Motility, 2. - 6. Oktober 2002, Tübingen
11. Cannabinoid CB₁-Rezeptoren modulieren die Neurotransmission am Magenfundus der Ratte. Arbeitskreis Neurogastroenterologie und Motilität e.V., 4.-6. März, Tutzing, 2001
12. Involvement of cannabinoids in neural transmission in rat gastric fundus. AGA Research Forum – Gastric sensation: Basic and clinical. DDW, 22. Mai, Atlanta/USA, 2001
13. Behandlung des symptomatischen Diffusen Ösophagusspasmus mit Botulinum Toxin: Eine prospektive Studie mit langzeit follow up. Arbeitskreis Neurogastroenterologie und Motilität e.V., 5.-7. März, Tutzing, 2000
14. Autonome Modulation des Einflusses des N.vagus auf die Muskulatur des Ösophagus der Ratte – Einfluss von Endomorphin 1 und 2. 54. Tagung der DGVS, 22.-25. September, Leipzig, 1999
15. Charakterisierung der autonomen Modulation der vagalen Innervation der Ösophaguskulatur an der Ratte. Arbeitskreis Gastrointestinale Motilität und Funktion, Tutzing, Februar 1999

Moderator and organization of Meetings

1. Organisation: Reizdarm-Update 2013, Effiziente Diagnostik und rationaler Einsatz neuer Therapiestrategien. 17.6.2013, München
2. Organisation: Reizdarm-Update 2012 Effiziente Diagnostik und rationaler Einsatz neuer Therapiestrategien. 10. 10. 2012, München
3. Session Chair: Reizdarmsyndrom: Entschlüsselung der Pathomechanismen als Basis therapeutischer Perspektiven im Rahmen der 67. Jahrestagung der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS). 20.9.2012 Hamburg
4. Session Chair: Clinical constipation, DDW, 7-10 May 2011, Chicago, USA
5. Organisation Workshop Enteric Regulation at the , 9th IFFGD Symposium, 8-10 April 2011, Milwaukee, USA
6. Session Chair: Enteric Regulation, 9th IFFGD Symposium, 8-10 April 2011, Milwaukee, USA
7. Session Chair: Enteric Nervous System & Neuroendocrine Function at the GIRG Meeting 19. March 2011 Banff, Canada
8. Chair Session V: Phyto-/Pharmaka, Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V. 28-30 March 2009, Schloss Hohenkammer bei Freising
9. Chair DDW Forum: – Pharmacotherapeutics of Functional GI and Motility Disorders. American Gastroenterology Association (AGA) Council Section: Neurogastroenterology & Motility. Digestive Disease Week (DDW), San Diego, May 21, 2008
10. Chair DDW Forum: – Pharmacotherapeutics of Functional GI and Motility Disorders. American Gastroenterology Association (AGA) Council Section: Neurogastroenterology & Motility. Digestive Disease week (DDW), Washington, May 2007
11. Chair Session III: Enteric Nervous System, Deutsche Gesellschaft für Neurogastroenterologie und Motilität. Schloss Hohenkammer bei Freising 2006
12. Chair Session III: Enteric Nervous System, Deutsche Gesellschaft für Neurogastroenterologie und Motilität. Tutzing 2005
13. Manometrikurs im Rahmen des 1. Gastroforums, 13.-14. 12.2002, München

Examiner activities

- OSCE Examiner in Internal Medicine and Gastroenterology, Modul 3, 2007 – ongoing
- Regular examiner in medical exams (German 2nd and 3rd State-exam) 2005 – ongoing
- Regular examiner in MD-thesis exams (Promotionsprüfer) 2005 – ongoing
- Examiner: Internal Medicine R3 oral exam (May 2009, Feb 2010)
- Examiner: Western GI-OCSE -Gastroenterology (Mar 2009)
- Examiner: Royal College Exam -Gastroenterology (Feb 2009)

CME Tutor activities

- Ultrasound of the Abdomen, 20.-23.3.2013 Munich
- Practical Endoscopy Training, DEGEA-Workshop, 14.3.2013, Munich
- Ultrasound of the Abdomen, 8.-13.10.2012 Munich
- Ultrasound of the Abdomen, 5.10.-8.10.2011 Munich
- Advanced Endoscopy, variceal bleeding; GATE course Munich 07.10.2011
- Advanced Endoscopy, duodenal pathologies; GATE course Munich, since 2006, annual
- Esophageal Manometry - Gastroforum, 2002-2006, Munich

Scholar-Education

- Orientierungstag der Münchner Gymnasiasten, Kleingruppenorientierung

Specialist Physiotherapists and Nurse Education

(Fachweiterbildung Endoskopie ekw.concept)

- Special training for endoscopy nurses, 2013 - ongoing, course: stomach pathologies
- Special training for endoscopy nurses, 2013 - ongoing, course: small intestinal pathologies
- Course 1 - Pathology for Physiotherapists, 2011, Munich

Lehrtätigkeit / Graduate and Undergraduate Education

2013 and ongoing (LMU München, Medical School – regulars)

- 7M2801 Bedside Teaching – OB GI System / ganztägiger Untersuchungskurs
- 7M1303 Seminar – Gastrointestinal Bleeding
- PJ-Seminar Erkrankungen und Leitsymptome / Diseases and cardinal symptoms
- PJ Seminar Reflux, Barrett, Gastritis, Ulkus
- Supervision undergraduate MD-Thesis Students
- Tutor – observership GI-outpatient clinic – Kurs ambulante Medizin (7M-3202), weekly
- 7M1303 Seminar gastrointestinales System – GI Funktionstests

2011 - 2012 (LMU München, Medical School – regulars)

- Seminar – Gastrointestinal diagnostics
- 7M2801 Bedside Teaching – OB GI System / ganztägiger Untersuchungskurs
- Tutorial Gastrointestinal System
- Seminar - Functional Diarrhea and Constipation
- PJ-Seminar Erkrankungen und Leitsymptome / Diseases and cardinal symptoms
- Supervision undergraduate MD-Thesis Students
- 7M1315 Blockpraktikum Innere Medizin im Rahmen von Modul 23

- 7M1303 Seminar gastrointestinales System– GI Funktionstests

2010 (University of Calgary, Medical School / Canada)

- UME – Course 1 – Lecture: Gut Sensation & Visceral Pain
- UME – Course 1 – GI Clinical correlation teaching
- FMC – UofC - Bedside Teaching (clinical Clerks, Residents and Fellows 4hrs/week)
- UME – Course 1 – Small group teaching (4 x 2hrs)
- Supervision post-doctoral fellows
- Supervision resident and fellow research
- Supervision PhD student (Dept of Physiology)

2009 (University of Calgary, Medical School / Canada)

- UME – Course 1 – GI Clinical Core – 6hours August 10 – October 16, 2009
- FMC – UofC - Bedside Teaching (clinical Clerks, Residents and Fellows 4hrs/week)
- Supervision post-doctoral fellows
- Supervision resident and fellow research
- Supervision PhD student (Dept of Physiology)

2008 (University of Calgary, Medical School / Canada)

- UME – Course 1 – Clinical correlation teaching
- UME – Course 1 – Small group teaching (4 x 2hrs)
- FMC – UofC - Bedside Teaching (clinical Clerks, Residents and Fellows 4hrs/week)
- Supervision post-doctoral fellows
- Supervision resident and fellow research
- Supervision PhD student (Dept of Physiology)
- PGME – Clinical Core Session – September 9, 2008, 1 hour

2007 (University of Calgary, Medical School / Canada)

- UME – Course 1 – Lecture: Digestion & Absorption
- UME – Course 1 – Small group teaching
- FMC – UofC - Bedside Teaching (clinical Clerks, Residents and Fellows 4hrs/week)
- Supervision post-doctoral fellows
- Supervision resident and fellow research

2004 - 2006 (LMU München, Medical School – regulars)

- 7M2801 Bedside Teaching – OB GI System 7 ganztägiger Untersuchungskurs
- Tutorial Gastrointestinal System
- PJ-Seminar Erkrankungen und Leitsymptome / Diseases and cardinal symptoms
- Supervision undergraduate MD-Thesis Students
- Blockpraktikum Innere Medizin

1998 - 2003 (TU München, Medical School – regulars)

- Bedside Teaching
- klinischer Untersuchungskurs für erstes klinisches Semester
- Innere Medizin am Krankenbett (Kurs)

Publications/Presentations:

1. Yan LM, Velkova A, Tatarek-Nossol M, Rammes G, Sibaev A, Andretto E, Kracklauer M, Bakou M, Malideli E, Göke B, Schirra J, **Storr M**, Kapurniotu A. Selectively N-Methylated Soluble IAPP Mimics as Potent IAPP Receptor Agonists and Nanomolar Inhibitors of Cytotoxic Self-Assembly of Both IAPP and A β 40. *Angew Chem Int Ed Engl*. 2013 Aug 19. doi: 10.1002/anie.201302840. [Epub ahead of print] (Impact Factor: 13,7)
2. Linton MS, Zhao L, Gui X, **Storr M**, Andrews CN. Lichen planus is an uncommon cause of nonspecific proximal esophageal inflammation. *Gut Liver*. 2013 Jul;7(4):401-5. (Impact Factor: 1,3)
3. Li YY, Cao MH, Goetz B, Chen CQ, Feng YJ, Chen CJ, Kasperek MS, Sibaev A, **Storr M**, Kreis ME. The dual effect of cannabinoid receptor-1 deficiency on the murine postoperative ileus. *PLoS One*. 2013 Jul 3;8(7):e67427. (Impact Factor: 3,7)
4. Sobczak M, Sałaga M, **Storr M**, Fichna J. Nociceptin / Orphanin FQ (NOP) Receptors as Novel Potential Target in the Treatment of Gastrointestinal Diseases. *Curr Drug Targets*. 2013 Sep;14(10):1203-9. (Impact Factor: 3,9)
5. Stewart MJ, Shaffer E, Urbanski SJ, Beck PL, Storr MA. The association between celiac disease and eosinophilic esophagitis in children and adults. *BMC Gastroenterol*. 2013 May 30;13:96. doi: 10.1186/1471-230X-13-96. (Impact Factor: 2,1)
6. Fichna J, Sibaev A, Sałaga M, Sobczak M, **Storr M**. The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice. *Neurogastroenterol Motil*. 2013 Aug;25(8):e550-9. (Impact Factor: 2,9)
7. Storr MA. Microscopic colitis: epidemiology, pathophysiology, diagnosis and current management-an update 2013. *ISRN Gastroenterol*. 2013 Apr 18;2013:352718.
8. **Storr M**, Vogel HJ, Schicho R. Metabolomics: is it useful for inflammatory bowel diseases? *Curr Opin Gastroenterol*. 2013 Jul;29(4):378-83. (Impact Factor: 4,1)
9. Li K, Fichna J, Schicho R, Saur D, Bashashati M, Mackie K, Li Y, Zimmer A, Göke B, Sharkey KA, **Storr M**. A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. *Neuropharmacology*. 2013 Aug;71:255-63. (Impact Factor: 4,1)
10. Klein S, Seidler B, Kettenberger A, Sibaev A, Rohn M, Feil R, Allescher HD, Vanderwinden JM, Hofmann F, Schemann M, Rad R, Storr MA, Schmid RM, Schneider G, Saur D. Interstitial cells of Cajal integrate excitatory and inhibitory neurotransmission with intestinal slow-wave activity. *Nat Commun*. 2013;4:1630. (Impact Factor: 10,0)
11. Sobczak M, Sałaga M, Storr MA, Fichna J. Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. *J Gastroenterol*. 2013 Feb 9. [Epub ahead of print] (Impact Factor: 3,8)
12. Li YY, Yuece B, Cao HM, Lin HX, Lv S, Chen JC, Ochs S, Sibaev A, Deindl E, Schaefer C, **Storr M**. Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis. *Lab Invest*. 2013 Mar;93(3):322-33. (Impact Factor: 4,0)
13. Fichna J, Lapointe T, Chapman K, Janecka A, Vergnolle N, Altier C, Storr MA. New neostigmine-based behavioral mouse model of abdominal pain. *Pharmacol Rep*. 2012;64(5):1146-54. (Impact Factor: 2,0)
14. Pehl C, Keller J, Allescher HD, Feussner H, Frieling T, Goebel-Stengel M, Gschossmann J, Kuhlbusch-Zicklam R, Mönnikes H, Nguyen HN, Müller M, Schirra J, **Storr M**, van der Voort I, Yüce B. Diagnosis of oesophageal reflux by PH, impedance, and bilirubin

- measurement: recommendations of the German Society of Neurogastroenterology and of the working group for neurogastroenterology of the German Society for Digestive and Metabolic Diseases. *Z Gastroenterol.* 2012 Dec;50(12):1310-32. (Impact Factor: 1,4)
15. Michler T, **Storr M**, Kramer J, Ochs S, Malo A, Reu S, Göke B, Schäfer C. Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms. *Am J Physiol Gastrointest Liver Physiol.* 2013 Jan 15;304(2):G181-92. (Impact Factor: 3,7)
 16. Kaplan GG, Szyszkowicz M, Fichna J, Rowe BH, Porada E, Vincent R, Madsen K, Ghosh S, **Storr M**. Non-specific abdominal pain and air pollution: a novel association. *PLoS One.* 2012;7(10):e47669. (Impact Factor: 3,7)
 17. Schicho R, **Storr M**. A potential role for GPR55 in gastrointestinal functions. *Curr Opin Pharmacol.* 2012 Dec;12(6):653-8. (Impact Factor: 5,4)
 18. Syed AA, Andrews CN, Shaffer E, Urbanski SJ, Beck P, **Storr M**. The rising incidence of eosinophilic oesophagitis is associated with increasing biopsy rates: a population-based study. *Aliment Pharmacol Ther.* 2012 Nov;36(10):950-8. (Impact Factor: 4,6)
 19. Bashashati M, Rezaei N, Bashashati H, Shafieyoun A, Daryani NE, Sharkey KA, **Storr M**. Cytokine gene polymorphisms are associated with irritable bowel syndrome: a systematic review and meta-analysis. *Neurogastroenterol Motil.* 2012 Dec;24(12):1102-e566. (Impact Factor: 2,9)
 20. Andrews CN, Beck PL, Wilsack L, Urbanski SJ, **Storr M**. Evaluation of endoscopist and pathologist factors affecting the incidence of microscopic colitis. *Can J Gastroenterol.* 2012 Aug;26(8):515-20. (Impact Factor: 1,5)
 21. Fichna J, Mokrowiecka A, Cygankiewicz AI, Zakrzewski PK, Małeczka-Panas E, Janecka A, Krajewska WM, Storr MA. Transient receptor potential vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for inflammatory bowel diseases treatment? *Neurogastroenterol Motil.* 2012 Nov;24(11):e557-60. (Impact Factor: 2,9)
 22. Li K, Feng JY, Li YY, Yuece B, Lin XH, Yu LY, Li YN, Feng YJ, **Storr M**. Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice. *Pancreas.* 2013 Jan;42(1):123-9. (Impact Factor: 3,0)
 23. Fichna J, Storr MA. Brain-Gut Interactions in IBS. *Front. Pharmacol.* 2012;3:127.
 24. Stewart, M., S. Kumar, C Seow, **M. Storr**: Interventions for induction and maintenance of mucosal healing in Crohn's disease. The Cochrane Library, Cochrane.org <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010141/full> 17.10.2012 (Impact Factor: 6,2)
 25. Synthesis and Opioid Activity of Novel 6-Ketolevorphanol Derivatives. Gyulai Z, Udvardy A, Bényei AC, Fichna J, Gach K, **Storr M**, Tóth G, Antus S, Berényi S, Janecka A, Sipos A. *Med Chem.* 2012 Jun 25. [Epub ahead of print] (Impact Factor: 1.5)
 26. Rezaie A, Cheng EJ, Jijon HB, Kumar S, Storr M. Prucalopride for the treatment of chronic constipation. The Cochrane Library, Cochrane.org <http://summaries.cochrane.org/CD009636/prucalopride-for-the-treatment-of-chronic-constipation>, 15.2.2012 (Impact Factor: 6,2)
 27. Andrews CN, Sadowski DC, Lazarescu A, Williams C, Neshev E, **Storr M**, Au F, Heitman S. Unsedated peroral wireless pH capsule placement vs. standard pH testing: A randomized study and cost analysis. *BMC Gastroenterol.* 2012 May 31;12(1):58. (Impact Factor: 2.4)
 28. Schicho R, Shaykhutdinov R, Ngo J, Nazyrova A, Schneider C, Panaccione R, Kaplan GG, Vogel HJ, **Storr M**. Quantitative Metabolomic Profiling of Serum, Plasma, and Urine by (1)H NMR Spectroscopy Discriminates between Patients with Inflammatory

- Bowel Disease and Healthy Individuals. *J Proteome Res.* 2012 May 17. [Epub ahead of print] (Impact Factor: 5.1)
29. Schicho R, **Storr M.** Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice. *Pharmacology.* 2012;89(3-4):149-55. (Impact Factor: 1.8)
 30. Bassaganya-Riera J, Viladomiu M, Pedragosa M, De Simone C, Carbo A, Shaykhtudinov R, Jobin C, Arthur JC, Corl BA, Vogel H, **Storr M**, Hontecillas R. Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR γ to suppress colitis. *PLoS One.* 2012;7(2):e31238 (Impact Factor: 4.1)
 31. Mohammad Bashashati, Nima Rezaei, Christopher N. Andrews, Chun-Qiu Chen, Nasser Ebrahimi Daryani, Keith A. Sharkey, **Martin A. Storr:** Cytokines and Irritable Bowel Syndrome: Where Do We Stand? *Cytokine*, 57 (2), 201-9, 2012 (Impact Factor: 3.0)
 32. Ian M. Hons, **Martin A. Storr**, Ken Mackie, Beat Lutz, Quentin J. Pittman, Gary M. Mawe, Keith A. Sharkey: Plasticity of mouse enteric synapses mediated through endocannabinoid and purinergic signaling *Neurogastroenterol Motil.* 24 (3), e113-24, 2012 (Impact Factor: 3.4)
 33. Chen Q, Fichna J, Bashashati M, Li, YY, **Storr M.:** Distribution, function and physiological role of melatonin in the lower gut. *World J Gastroenterol.* 17 (34), 3888-98, 2011 (Impact Factor: 2.5)
 34. Alfadda AA, **Storr MA**, Shaffer EA. Eosinophilic colitis: an update on pathophysiology and treatment. *Brit Med Bull.* 100, 59-72, 2011 (Impact Factor: 4.5)
 35. Fichna J, Dickey M, Lewellyn K, Janecka A, Zjawiony JK, Macnaughton WK, **Storr MA.** Salvinatorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors. *Inflamm Bowel Dis.* 18 (6), 1137-45, 2012 (Impact Factor: 4.9)
 36. **Storr, M.:** Chronic constipation: Current management and challenges. *Can J Gastroenterol* 2011, 25 (Suppl B), 5B-6B. (Impact Factor: 1.2)
 37. CN Andrews, **M. Storr:** The pathophysiology of chronic constipation. *Can J Gastroenterol* 2011, 25 (Suppl B), 16B-21B. (Impact Factor: 1.2)
 38. Bashashati M, Storr MA, Nikas SP, Wood JT, Godlewski G, Liu J, Ho W, Keenan CM, Zhang H, Alapafuja SO, Cravatt BF, Lutz B, Mackie K, Kunos G, Patel KD, Makriyannis A, Davison JS, Sharkey KA. Inhibiting fatty amide hydrolase normalizes endotoxin induced enhanced gastrointestinal motility in the mouse. *Br J Pharmacol.* 165 (5), 1556-71, 2012 (Impact Factor: 4.4)
 39. Schicho R, **Storr M.** Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases. *Can J Gastroenterol.* 2011 Jul;25(7):377-83. (Impact Factor: 1.2)
 40. Lin XH, Yuece B, Li YY, Feng YJ, Feng JY, Yu LY, Li K, Li YN, **Storr M.** A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. *Neurogastroenterol Motil.* 2011 Sep;23(9):862-e342. (Impact Factor: 3.4)
 41. Stewart MJ, Seow CH, **Storr MA.** Prednisolone and budesonide for short- and long-term treatment of microscopic colitis: systematic review and meta-analysis. *Clin Gastroenterol Hepatol.* 2011 Oct;9(10):881-90. (Impact Factor: 5.6)
 42. Congly, S. Gao, ZH., **Storr, M.:** Duodenal Vascular Ectasia [DUVE] Associated with Hematopoietic Stem Cell Transplant. *Endoscopy* 2011, 43 Suppl 2 UCTN:E197-8 (Impact Factor: 5.2)
 43. Stewart M, Andrews CN, Urbanski S, Beck PL, **Storr M:** The association of coeliac disease and microscopic colitis: a large population-based study. *Aliment Pharmacol Ther.* 2011 Jun;33(12):1340-9. (Impact Factor: 3.8)

44. Fichna J, Dickey M, Hirota SA, Traboulsi D, Macdonald JA, Janecka A, Beck PL, Zjawiony JK, Macnaughton WK, **Storr MA.**: Differential effects of salvinorin A on endotoxin-induced hypermotility and neurogenic ion transport in mouse ileum. *Neurogastroenterol Motil.* 2011 Jun;23(6):583-e212. (Impact Factor: 3.4)
45. Kurjak M, Fichna J, Harbarth J, Sennfelder A, Allescher HD, Schusdziarra V, Storr M, Otto B.: Effect of GABA-ergic mechanisms on synaptosomal NO synthesis and the nitregeric component of NANC relaxation in rat ileum. *Neurogastroenterol Motil.* 2011 May;23(5):e181-e190. (Impact Factor: 3.4)
46. Andrews CN, Mintchev P, Neshev E, Fraser HF, Storr M, Bathe OF, Urbanski SJ.: Percutaneous endoscopically assisted transenteric full-thickness gastric biopsy: initial experience in humans. *Gastrointest Endosc.* 2011 May;73(5):949-54. (Impact Factor: 4.9)
47. **Storr, M.**: What is nonacid reflux disease? *Can. J. Gastro.* 25(1): 38-38. (Impact Factor: 1.2)
48. Schicho R, Bashashati M, Bawa M, McHugh D, Saur D, Hu HM, Zimmer A, Lutz B, Mackie K, Bradshaw HB, McCafferty DM, Sharkey KA, **Storr M.**: The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. *Inflamm Bowel Dis.* 2011 Aug;17(8):1651-64 (Impact Factor: 4.9)
49. Alfadda A., Storr M., Shaffer, E.:Eosinophilic colitis: epidemiology, clinical features and current management. *Therapeutic Advances in Gastroenterology.* 2011 Sep;4(5):301-9.
50. Schicho R, Nazyrova A, Shaykhutdinov R, Duggan G, Vogel HJ, **Storr M.**: Quantitative Metabolomic Profiling of Serum and Urine in DSS-Induced Ulcerative Colitis of Mice by (1)H NMR Spectroscopy. *J Proteome Res.* 9(12):6265-73, 2010. (Impact Factor: 5.1)
51. Papay, K.D., Falck, V.G., Poulsen, SS., Panaccione, R., Rehfeld, J.F., **Storr, M.**: Juvenile polyposis of the stomach-a novel cause of hypergastrinemia. *Nat Rev Gastroenterol Hepatol.* 2010 Oct;7(10):583-8 (Impact Factor: 8.1)
52. Czakó B., Marton J., Berényi S., Sipos A., Gach K., Fichna J., Storr M., Toth G., Janecka A.: Synthesis and opioid activity of novel 6-substituted-6-demetoxy-ethendomorphins. *Bioorganic & Medicinal Chemistry*, 18(10):3535-42, 2010. (Impact Factor: 2.9)
53. Gach, K., do-Rego, J.C., Fichna, J., Storr, M., Delbro, D., Toth, G., Janecka. A.: Synthesis and biological evaluation of novel peripherally active morphiceptin analogs. *Peptides*, 31(8):1617-24, 2010 (Impact Factor: 2.4)
54. Bashashati M., Andrews C., Ghosh S., **Storr M.**: Botulinum toxin in the treatment of diffuse esophageal spasm. *Diseases of the Esophagus*, 23(7):554-560, 2010. (Impact Factor: 1.8)
55. Fichna J., Perlikowska R., Gach K., Bashashati M., Li K., Schicho R., do-Rego J-C., Cravezic A., Bonnet J.J., Janecka A., **Storr M.**: The novel endomorphin degradation blockers Tyr-Pro-DCIPhe-Phe-NH₂ (EMDB-1) and tyr-Pro-Ala-NH₂ (EMDB-2) prolong endomorphin-2 action in rat ileum. *Chemical Biology & Drug Design*, 76(1):77-81, 2010. (Impact Factor: 2.3)
56. Yüce B., Kemmer M., Qian, G., Müller M., Sibaev A., Li YY, Kreis M.E., **Storr M.**: Cannabinoid 1 (CB₁) receptors modulate intestinal sensory and motor function in rats. *Neurogastroenterology and Motility.* 22(6):672-e205, 2010. (Impact Factor: 3.4)
57. **Storr M.A.**, Bashashati M., Hirota C., Vemuri V.K., Keenan C.M., Duncan M., Lutz B., Mackie K., Makriyannis A., MacNaughton W.K., Sharkey K.A.: Differential effects of CB₁ neutral antagonists and inverse agonists on gastrointestinal motility in mice. *Neurogastroenterology and Motility*, 22(7): 787-e223, 2010. (Impact Factor: 3.4)
58. Fichna J., Gach K., Perlikowska R., Cravezic A., Bonnet J.J., do-Rego J-C., Janecka A., Storr M.A.: Novel endomorphin analogs with antagonist activity at the mu opioid

- receptor in the gastrointestinal tract. *Regulatory Peptides*, 162 (1-3) 109-14, 2010. (Impact Factor: 2.1)
59. Schicho R., **Storr M.**: Targeting the endocannabinoid system for gastrointestinal diseases: implications for future therapeutic strategies. *Exp. Rev. Clin. Pharmacol.* 3 (2), 193-207, 2010.
 60. Fraser, H., Neshev E., Storr M., Urbanski S.J., Andrews C.N.: A novel method of full-thickness gastric biopsy via a percutaneous endoscopically-assisted transenteric (PEATE) approach. *Gastrointestinal Endoscopy*, 71(4), 831-4, 2010. (Impact Factor: 4.9)
 61. **Storr M**, Emmerdinger D, Diegelmann J, Pfennig S, Ochsenkühn T, Göke B, Lohse P, Brand S.: The cannabinoid 1 receptor (CNR1) 1359 G/A polymorphism modulates susceptibility to ulcerative colitis and the phenotype in Crohn's disease. *PLoS One*. 2010 Feb 26;5(2):e9453. (Impact Factor: 4.1)
 62. Williams J. J., Beck P.L., Andrews C.N., Hogan D.B., **Storr M.A.**: Microscopic colitis: a common cause of diarrhea in older adults. *Age and Ageing*, 39(2), 162-8, 2010. (Impact Factor: 3.1)
 63. Lee, R., Storr, M., Hershfield, NB. A case of Conn syndrome revealed after oral sodium phosphate (fleet) preparation for colonoscopy. *Journal of Digestive Diseases*, 11 (2), 111-114, 2010 (Impact Factor: 1.6)
 64. Li, YY., Li, YN., Ni, JB., Chen CJ., Lv, S., Chai, SY., Wu, RH., Yuce, B., **Storr, M.**: Involvement of cannabinoid-1 and cannabinoid-2 receptors in septic ileus. *Neurogastroenterology and Motility*, 22(3), 350-e88, 2010 (Impact Factor: 3.4)
 65. Fichna J, Schicho R, Janecka A, Zjawiony JK, **Storr M**. Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction. *Drug News Perspect.* 2009 Sep;22(7):383-92. (Impact Factor: 2.2)
 66. Perlikowska, R., Fichna, J., Wyrebska, A., Poels, J., Van den Broeck, J., Toth, G., Storr, M., do Rego, JC., Janecka, A.: Design, synthesis and pharmacological characterization of endomorphin analogs with non-cyclic amino acid residues in position 2. *Basic Clin. Pharmacol. Toxicol.* Feb;106(2):106-13, 2010 (Impact Factor: 2.2)
 67. Fichna, J., Schicho, R., Andrews, CN., Bashashati, M., Klompus, M., McKay, DM., Sharkey, KA., Zjawiony, J., Janecka, A., **Storr, M.**: Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating κ -opioid and cannabinoid receptors. *Neurogastroenterology and Motility*, Dec;21(12):1326-e128, 2009 (Impact Factor: 3.4)
 68. Keller, J., Fox, M., Nicolaus, M., Schirra, J. Van der Vort, I., Fox, M., **Storr, M.**: Performance and Interpretation of Esophageal Manometry: Recommendations of the German Societies for Neurogastroenterology and Motility (DGNM), for Digestive and Metabolic Diseases (DGVS) and for General and Visceral Surgery (DGAV)., *ZFG*, 47(9):830-845, 2009 (Impact Factor: 0.9)
 69. **Storr, M.**, Keenan, C., Zhang, H., Patel, K.D., Makriyannis, A., Sharkey, K.A.: Activation of the cannabinoid 2 receptor (CB₂) protects against experimental colitis. *IBD* Nov;15(11):1678-85, 2009 (Impact Factor: 4.9)
 70. Mueller MH, Gong Q, Kelber O, Kasperek MS, Sibaev A, Mansmann U, Yuce B, Li YY, Storr M, Kreis ME. A novel herbal preparation desensitizes mesenteric afferents to bradykinin in the rat small intestine. *Neurogastroenterol Motil*, 21(4):467-76, 2009 (Impact Factor: 3.4)
 71. **Storr, M.**, Emmerdinger, D., Diegelmann, J., Yuce, B., Pfennig, S., Ochsenkühn, T., Göke, B., Lohse, P., Brand, S.: The role of fatty acid hydrolase (FAAH) gene variants in inflammatory bowel disease. *Aliment Pharmacol Ther.*, 29(5):542-51, 2009 (Impact Factor: 3.8)

72. **Sibaev, A.,** Yuece, B., Kemmer, M., Van Nassauw, L., Broedl, U.C., Allescher H.D., Goeke, B., Timmermans, J.P., **Storr, M.:** Cannabinoid -1 (CB1) receptors regulate colonic propulsion by acting at motor neurons within the ascending motor pathways in mouse colon. *Am J Physiol Gastrointest Liver Physiol.* 296(1):G119-28, 2009 (Impact Factor: 3.4)
73. **Storr, M.,** Gao Z.H., Hershfield, N.: Nonprogressive, Long-term dysphagia in a patient with esophageal Lichen Planus. *Clin Gastroenterol Hepatol.* 7(3):A24, 2009 (Impact Factor: 5.6)
74. Kurjak, M., Hamel A.M., Allescher H.D., Schusdziarra V., **Storr, M.:** Differential stimulatory effects of cannabinoids on VIP release and NO synthase activity in synaptosomal fractions from rat ileum. *Neuropeptides,* 42 (5-6):623-32, 2008 (Impact Factor: 1.6)
75. Andrews, C.N., **Storr, M.:** Evaluation of Lower Functional Gut Disorders. *Canadian Journal of Gastroenterology,* 22(7), 614-6, 2008 (Impact Factor: 1.2)
76. **Storr, M.,** Yuece, B., Andrews, C.N., Sharkey, K.A.: The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. *Neurogastroenterology and Motility,* 20(8), 857-68, 2008 (Impact Factor: 3.4)
77. **Storr, M.,** Andrews, C.N.: Medical Management of Irritable Bowel Syndrome in 2008: Current and Future Directions. *Canadian Journal of Gastroenterology,* 22(8), 673-5, 2008 (Impact Factor: 1.2)
78. **Storr M.,** Keenan C.M., Emmerdinger D., Zhang H., Yüce B., Sibaev A., Massa F., Buckley N.E., Lutz B., Göke B., Brand S., Patel K.D., Sharkey K.A.: Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB(1) and CB (2) receptors. *J Mol Med,* 86(8), 925-36, 2008 (**Impact Factor:** 5.2)
79. Sibaev, A., Yüce, B. Göke, B., Allescher, H.D., **Storr, M.:** A new electrophysiological tool to investigate the spatial neuronal projections within the myenteric ascending reflex of mouse colon. *CEPP,* 35(7):744-50, 2008 (Impact Factor: 1.8)
80. **Storr, M.:** Functional results after extended myotomy for diffuse oesophageal spasm. *Br J Surg,* 95(1):125, 2008 (Impact Factor: 4.1)
81. **Storr, M.,** Sharkey K.A.: The endocannabinoid system and brain-gut signalling. *Current Opinion in Pharmacology,* 7(6): 575-582, 2007 (Impact Factor: 6.9)
82. Yuece, B., Sibaev, A., Broedl, U., Marsicano, G., Goeke, B., Lutz, B., Allescher, H.D., **Storr, M.:** Cannabinoid type 1 receptor modulates intestinal propulsion by an attenuation of intestinal motor responses within the peristaltic reflex. *Neurogastroenterol Motil,* 19(9):744-53, 2007 (Impact Factor: 3.4)
83. **Storr, M.:** TRPV1 in colitis: is it a good or a bad receptor? A viewpoint. *Neurogastroenterology and Motility,* 19(8):625-9, 2007 (Impact Factor: 3.4)
84. Yuece, B., Sibaev, A., Haaken, A., Saur, D., Allescher, H.D., Goeke, B., Timmermans, J.P., **Storr, M.:** ORL-1 receptor mediates the action of nociceptin on ascending myenteric reflex pathways in rodents. *Gastroenterology,* 133(2):574-86, 2007 (Impact Factor: 12.5)
85. Brand, S., Dambacher, J., Beigel, F., Zitzmann, K., Heeg, M., Weiss, T., Prüfer, T., Olszak, T., Steib, C., **Storr, M.,** Göke, B., Diepolder, H., Bilzer, M., Thasler, W., Auernhammer, C.: IL-22 mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. *Am J. Physiol,* 292(4):G1019-28, 2007 (Impact Factor: 3.7)
86. Li, Y.Y., Sibaev, A., Zhou, M.Z., Zhu, G.Y., Yuece, B., **Storr, M.:** The chinese herbal preparation Qing Yi Tang (QYT) improves intestinal myoelectrical activity and increases intestinal transit during acute pancreatitis in rodents. *Phytotherapy Research,* 21(4):324-31, 2007 (Impact Factor: 2.1)

87. Sibaev, A., Yüce, B., Kelber, O., Weiser, D., Schirra, J., Göke, B., Allescher, H.D., **Storr, M.**: STW5 (Iberogast) and its individual herbal components modulate intestinal electrophysiology of mice. *Phytomedicine*, 13(Suppl 1), 80-89, 2006 (Impact Factor: 1.4)
88. Sibaev, A., Yüce, B., Schirra, J., Göke, B., Allescher, H.D., **Storr, M.**: Are different gap junctions involved in neuromuscular interaction in mouse proximal colon? *CEPP*, 33, 740-745, 2006 (**Impact Factor: 1.8**)
89. **Storr, M.**, Göke, B., Wagner, A.: Unusual cause of azathioprine inefficacy. *Endoscopy*, 38(S2), E61, 2006 (Impact Factor: 3.6)
90. **Storr, M.**, Göke, B., Diepolder, H.: Unusual cause of intractable vomiting after cisplatin chemotherapy. *Endoscopy*, 38(S2), E54, 2006 (Impact Factor: 3.6)
91. Ulsenheimer, A., Schirra, J., Göke, B., **Storr, M.**: Enterothorax mimicking pleural effusion. *Indian Journal of Gastroenterology*, 25(3), 146, 2006
92. **Storr, M.**, Yüce, B., Göke, B.: Perspektiven von Cannabinoiden in der Gastroenterologie. *Zeitschrift für Gastroenterologie*, 44, 185-191, 2006 (Impact Factor: 0.9)
93. Massa, F., **Storr, M.**, Lutz, B.: The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. *Journal of Molecular Medicine*, 83(12), 944-54, 2006 (Impact Factor: 5.2)
94. Vogeser, M., Hauer, D., Azad, S., Huber, D., **Storr, M.**, Schelling, G.: Ex-vivo release of anandamide from blood cells. *Clinical Chemistry Laboratory Medicine*, 44(4), 488-491, 2006 (Impact Factor: 1.7)
95. Sibaev, A., Massa, F., Yüce, B., Marsicano, G., Lehr, H.A., Lutz, B., Göke, B., Allescher, H.D., **Storr, M.**: CB1 and TRPV1 receptors mediate protective effects on electrophysiological properties during colonic inflammation. *J Mol Med*, 84(6), 513-520, 2006 (Impact Factor: 5.2)
96. Massa, F., Sibaev, A., Marsicano, G., Hermann, H., **Storr, M.**, Lutz, B.: Protective function of vanilloid receptor TRPV1 in colonic inflammation. *J Mol Med*, 84(2), 142-146, 2006 (Impact Factor: 5.2)
97. Schirra, J., Nicolaus, M., Roggel, R., Katschinski, M., **Storr, M.**, Woerle, H.J., Göke, B.: Endogenous GLP-1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in human. *Gut*, 55(2), 243-251, 2006 (Impact Factor: 9.0)
98. **Storr, M.**, Allescher, H.D.: Endoskopisch-interventionelle Maßnahmen beim Zenker Divertikel. *Verdauungskrankheiten*, 26(6), 264-269, 2005
99. Keller, J., Franke, A., **Storr, M.**, Wiedbrauck, F., Schirra, J.: Klinisch relevante Atemtests in der gastroenterologischen Diagnostik. Empfehlungen der Deutschen Gesellschaft für Neurogastroenterologie und Motilität sowie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten. *Zeitschrift für Gastroenterologie*, 43, 1171-1190, 2005 (Impact Factor: 1.3)
100. Seiderer, J., **Storr, M.**, Szukics, B., Schäfer, C., Göke, B., Schirra, J.: Gastrointestinale Störungen im Senium: Prädisposition für eine Krankheit? *Bayerischer Internist*, 25(1), 8-17, 2005
101. **Storr, M.**: Balloon dilatation in patients with diffuse esophageal spasm. *Gastrointestinal Endoscopy*, 61 (3), 501, 2005 (Impact Factor: 4.9)
102. **Storr, M.**, Linke, R., Nicolaus, M., Göke, B., Schirra, J.: Endoskopische Injektion von Botulinumtoxin A bei einem Patienten mit diffusem Ösophagusspasmus. *Deutsche Medizinische Wochenschrift*, 130 (6), 266-269, 2005 (Impact Factor: 0.8)
103. Allescher, H.D., **Storr, M.**: Management der Dysphagie – Sicht des Gastroenterologen. *Endoskopie heute*, 16, 200-207, 2004

104. Gündel, H., **Storr, M.**; Psychosomatiker und Internisten müssen zusammenarbeiten. Beim Reizdarm sind Sie im Team erfolgreicher. *MMW Fortschr Med*, 146 (29-30): 24-28, 2004
105. **Storr, M.**, Meining, A.: Pharmacologic management and treatment of gastroesophageal reflux disease. *Diseases of the Esophagus*, 17 (3):197-204, 2004 (Impact Factor: 1.77)
106. **Storr, M.**, Sibae, A., Weiser, D., Kelber, O., Schirra, J., Göke, B., Allescher, H.D.: Herbal extracts modulate the amplitude and frequency of slow waves in circular smooth muscle of mouse small intestine. *Digestion*, 70 (4), 257-264, 2004 (Impact Factor: 1.8)
107. Massa, F., Marsicano, G., Herman, H., Cannich, A., Monory, K., Cravatt, B.F., Ferri, G.L., Sibae, A., **Storr, M.**, Lutz, B.: The endogenous cannabinoid system protects against colonic inflammation. *J. Clin. Invest.*, 113 (8), 1202-1209, 2004 (Impact Factor: 14.1)
108. Meining, A., Fackler, A., Tzavella, K., **Storr, M.**, Allescher, H.D., Klauser, A., Heldwein, W.: Lower esophageal sphincter pressure in patients with gastroesophageal reflux diseases and posture and time patterns. *Diseases of the Esophagus*, 17 (2), 155-158, 2004 (Impact Factor: 1.77)
109. **Storr, M.**, Sibae, A., Marsicano, G., Lutz, B., Schusdziarra, V., Timmermans, J.P., Allescher, H.D.: Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. *Am J Physiol.*, 286 (1), G110-G117, 2004 (Impact Factor: 3.7)
110. Sibae, A., Franck, H., Vanderwinden, J.M., Allescher, H.D., **Storr, M.**: Structural differences in the enteric neural network in murine colon: impact on electrophysiology. *Am J Physiol*, 285 (6), G1325-G1334, 2003 (Impact Factor: 3.7)
111. **Storr, M.**, Sattler, D., Hahn, A., Schusdziarra, V., Allescher, H.D.: Role of endogenous cholecystokinin in the ascending excitatory reflex pathway of the rat ileum. *Neuropharmacology*, 44, 524-532, 2003 (Impact Factor: 3.9)
112. **Storr, M.**, Allescher, H.D.: Ursachen und therapeutische Möglichkeiten bei Störungen der gastrointestinalen Motilität. *Medizinische Monatsschrift für Pharmazeuten*, 26 (8), 260-269, 2003
113. Allescher, H.D., **Storr, M.**: Botulinum-Toxin. Internistische Indikationen. *Internist*, 43(12), 1566-1574, 2002
114. Geisler, F., **Storr, M.**, Fritsch, R., Rösch, T., Classen, M., Allescher, H.D.: Endoscopic treatment of a Zenker's diverticulum using argon plasma coagulation in a patient with massive cachexia and esophageal obstruction: a case report and review of literature. *Diseases of the Esophagus*, 15(2), 180-185, 2002 (Impact Factor: 1.4)
115. **Storr, M.**, Allescher, H.D.: Einsatz von Botulinum Toxin A im Gastrointestinaltrakt. *Medizinische Klinik*, 97(7), 396-401, 2002
116. Fritsch, R., **Storr, M.**, Geisler, F., Kurjak, M., Berger, H., Rösch, T., Allescher, H.D., Classen, M.: Simultaneous perforation of three major liver blood vessels including lobar hepatic artery and right portal vein by Percutaneous Transhepatic Biliary Drainage. *Endoscopy*, 34(10), 844, 2002 (Impact Factor: 1.8)
117. **Storr, M.**, Thammer, J., Dunkel, R., Schusdziarra, V., Allescher, H.D.: Modulatory effect of adenosine receptors on the ascending and descending neural reflexes of rat ileum peristalsis. *BMC Neuroscience*, 3, 21, 2002 (Impact Factor: 2.7)
118. **Storr, M.**, Born, P., Frimberger, E., Weigert, N., Roesch, T., Meining, A., Classen, M., Allescher, H.D.: Treatment of achalasia: the short-term response to botulinum toxin injection seems to be independent of any kind of pretreatment. *BMC Gastroenterology*, 2(1), 19, 2002, Correction: *BMC Gastroenterology*, 3(1), 32, 2003 (Impact Factor: 1.8)
119. **Storr, M.**, Koppitz, P., Sibajev, A., Saur, D., Kurjak, M., Franck, H., Schusdziarra, V., Allescher, H.D.: Melatonin reduces non-adrenergic, non-cholinergic relaxant

- neurotransmission by reducing nitric oxide synthase activity in the gastrointestinal tract of rodents in vitro. *Journal of Pineal Research*, 33(2), 101-108, 2002 (Impact Factor: 4.4)
120. **Storr, M.**, Gaffal, E., Schusdziarra, V., Allescher, H.D.: Endomorphin 1 and 2 reduce relaxant non-adrenergic, non-cholinergic neurotransmission in rat gastric fundus. *Life Sciences*, 71(4), 383-389, 2002 (Impact Factor: 2.5)
 121. Hahn, A., **Storr, M.**, Allescher, H.D.: Effect of tachykinins on the ascending and descending reflex pathway in rat small intestine. *Acta Pharmacologica Sinica* 23(4), 289-295, 2002 (Impact Factor: 0.4)
 122. **Storr, M.**, Hahn, A., Gaffal, E., Saur, D., Allescher, H.D.: Effects of endomorphin 1 and 2 on μ -opioid receptors on myenteric neurons and within the peristaltic reflex in rat small intestine. *Clinical and Experimental Pharmacology and Physiology*, 29, 428-434, 2002 (Impact Factor: 1.8)
 123. **Storr, M.**, Folmer, R., Kurjak, M., Schusdziarra, V., Allescher, H-D.: Okadaic acid inhibits relaxant neural transmission in rat gastric fundus in vitro. *Acta Physiologica Scandinavica*, 175(1), 29-36, 2002 (Impact Factor: 1.7)
 124. **Storr, M.**, Gaffal, E., Saur, D., Schusdziarra, V., Allescher, H.D.: Effect of cannabinoids on neural transmission in rat gastric fundus. *Canadian Journal of Physiology and Pharmacology*, 80(1), 67-76, 2002 (Impact Factor: 1.4)
 125. **Storr, M.**, Geisler, F., Neuhuber, W., Schusdziarra, V., Allescher, H-D.: Characterization of vagal input to the rat esophageal muscle. *Autonomic Neuroscience*, 91, 1-9, 2001 (Impact Factor: 1.4)
 126. **Storr, M.**, Allescher, H.D., Rösch, T., Born, P., Weigert, N., Classen, M.: Treatment of symptomatic diffuse esophageal spasm by endoscopic injection of botulinum toxin: A prospective study with long term follow up. *Gastrointestinal Endoscopy* 54(6), 754-759, 2001 (Impact Factor: 4.9)
 127. Allescher, H.D., **Storr, M.**, Seige, M., Gonzales-Donoso, R., Ott, R., Born, P., Frimberger, E., Weigert, N., Stier, A., Kurjak, M., Rösch, T., Classen, M.: Treatment of Achalasia: Botulinum toxin injection versus pneumatic balloon dilatation. A prospective study with long-term follow-up. *Endoscopy*, 33(12), 1007-1017, 2001 Correction: *Endoscopy*, 36(2), 185, 2004 (Impact Factor: 1.8)
 128. Gonzalez, R., **Storr, M.**, Bloching, H., Seige, M., Ott, R., Allescher, H.D.: Autoantibody profile in progressive systemic sclerosis as markers for esophageal involvement. *Journal of Clinical Gastroenterology*, 32(2), 123-127, 2001 (Impact Factor: 1.1)
 129. **Storr, M.**, Becker, I., Huber, W., Hohenleutner, U., Lersch, C.: Septischer Verlauf einer erworbenen reaktiv perforierenden Kollagenose durch Superinfektion der Hautläsionen. *Intensivmedizin*, 38(7), 570-575, 2001
 130. **Storr, M.**, Allescher, H.D.: Current concepts on pathophysiology, diagnosis and treatment of diffuse oesophageal spasm. *Drugs*, 61(5), 579-591, 2001 (Impact Factor: 4.0)
 131. **Storr, M.**, Meining, A., Allescher, H-D.: Pharmacoeconomic issues of the therapy of gastroesophageal reflux disease (GERD). *Expert Opinion of Pharmacotherapy*, 2 (7), 1099-1108, 2001 (Impact Factor: 1.1)
 132. **Storr, M.**, Weigert, N., Weiß, W., Allescher, H.D., Classen, M., Berger, H.: Haemosuccus pancreaticus – Eine seltene Komplikation der Pankreatitis. *Deutsche Medizinische Wochenschrift*, 126 (5), 108-112, 2001 (Impact Factor: 0.8)
 133. **Storr, M.**, Meining, A., Allescher, H-D.: Pathophysiology and pharmacological treatment of gastroesophageal reflux disease. *Digestive Diseases*, 18(2), 93-102, 2000 (Impact Factor: 1.5)

134. **Storr, M.**, Allescher, H-D.: Barrett-Ösophagus, gastroösophagealer Reflux und Helicobacter pylori als Risikofaktoren für das Adenokarzinom der Speiseröhre. Verdauungskrankheiten, 18(2), 57-62, 2000
135. **Storr, M.**, Franck, H., Saur, D., Schusdziarra, V., Allescher, H-D.: Mechanisms of ATP-induced inhibition in rat ileal smooth muscle – involvement of intracellular Ca²⁺-stores for purinergic induced inhibition. Clinical and Experimental Pharmacology and Physiology, 27, 771-779, 2000 (Impact Factor: 1.5)
136. Allescher, H.D., **Storr, M.**, Pillner, C., Brantl, V., Schusdziarra, V.: Effect of opioid active therapeutics on the ascending reflex pathway in the rat ileum. Neuropeptides, 34(3/4), 181-186, 2000 (Impact Factor: 1.4)
137. **Storr, M.**, Geisler, F., Neuhuber, W., Schusdziarra, V., Allescher, H-D.: Endomorphin 1 and 2, endogenous ligands for the μ -opioid receptor, inhibit striated and smooth muscle contraction in the rat esophagus. Neurogastroenterology and Motility 12, 441-448, 2000 (Impact Factor: 2.0)
138. Allescher, H.D., **Storr, M.**, Brechmann, C., Hahn, A., Schusdziarra, V.: Modulatory effect of endogenous and exogenous opioids on the excitatory reflex pathway of the rat ileum. Neuropeptides, 34(1), 62-68, 2000 (Impact Factor: 1.4)
139. **Storr, M.**, Schusdziarra, V., Allescher, H-D.: Inhibition of small conductance K⁺ channels attenuated melatonin-induced relaxation of serotonin contracted rat gastric fundus. Canadian Journal of Physiology and Pharmacology, 78(10), 799-806, 2000 (Impact Factor: 1.3)
140. **Storr, M.**, Allescher, H-D.: Esophageal pharmacology and treatment of primary motility disorders. Diseases of the Esophagus, 12, 241-257, 1999 (Impact Factor: 1.77)
141. Franck, H., **Storr, M.**, Puschmann, A., Schusdziarra, V., Allescher, H-D.: Involvement of intracellular Ca²⁺ stores in inhibitory effects of NO donor SIN-1 and cGMP. American Journal of Physiology, 275, G159 – G168, 1998 (Impact Factor: 3.2)
142. **Storr, M.**, Weigert, N., Fellbaum, C., Classen, M.: Polypose des Gastrointestinaltraktes als Manifestation der diffusen follikulären lymphatischen Hyperplasie. Deutsche Medizinische Wochenschrift, 123, 347 – 352, 1998 (Impact Factor: 0.8)
143. Huber, A., Trudrung, P., **Storr, M.**, Schusdziarra, V., Allescher, H-D.: Protein kinase G expression in the small intestine and functional importance for smooth muscle relaxation. American Journal of Physiology, 275, G629 – G637, 1998 (Impact Factor: 3.2)

Book chapters, commentaries and non-peer reviewed publications

1. **Storr, M.** Acotiamid lindert postprandiale dyspeptische Beschwerden. Med Monatsschr Pharm, 36 (10) 371-373, 2013
2. **Storr, M.** Bücherforum Arzneimittelwirkungen. Arzneimitteltherapie, 31 (5) 1140, 2013
3. **Storr, M.** Funktionelles Sodbrennen – Update 2013. MMW Originalienband IV 2013, S100-103
4. **Storr M.** GLP-2 Analog Teduglutide bei Short Bowel Syndrome. Med Monatsschr Pharm. 2013 36;5:343-345.
5. **Storr. M.:** Funktionsstörungen des Gastrointestinaltraktes im Rahmen des Diabetes mellitus, Diabetesforum 2013; 11; 34-41
6. V. Andresen, P. Enck, T. Frieling, R. Kiesslich, J. Labenz, P. Layer, S. Miehke, H. Mönnikes, C. Pehl, M. Schemann, **M. Storr, .:** Reizdarmsyndrom – Herausforderung in der täglichen Praxis. Thieme Praxis Report / Beilage in der DMW 2013; 5, 1-16

7. **Storr, M:** Eosinophile Ösophagitis: Verbesserung durch geschlucktes vernebeltes Fluticason und Esomeprazol. *Arzneimitteltherapie*, 31 (6) 174-175, 2013
8. **Storr, M:** Eosinophile Ösophagitis: Verbesserung durch geschlucktes vernebeltes Fluticason und Esomeprazol. *Med Monatsschr Pharm*, 36 (7) 270-272, 2013
9. **Storr, M:** Bücherforum – Mutschler Arzneimittelwirkungen. *Arzneimitteltherapie*, 31 (5) 140-141, 2013
10. **Storr M.** [Helicobacter pylori - Update 2013]. *Med Monatsschr Pharm*. 2013 May;36(5):172-6; quiz 177-8.
11. Ottillinger B, **Storr M**, Malfertheiner P, Allescher HD. STW 5 (Iberogast®)--a safe and effective standard in the treatment of functional gastrointestinal disorders. *Wien Med Wochenschr*. 2013 Feb;163(3-4):65-72.
12. **Storr, M.:** GERD: Die Refluxinhibitoren Baclofen und Lesogaberan enttäuschen in der klinischen Prüfung. *Med Monatsschr Pharm*, 2012, 35, 12, 468-470
13. **Storr, M.:** Update Sodbrennen – So löschen Sie den Brand. *Allgemeinarzt*, 2011, 17, 14-24.
14. **Storr, M.:** Therapy of gastrointestinal reflux disease (GERD). Aktuelle und zukünftige Therapien der gastroösophagealen Refluxerkrankung (GERD). *Med Monatsschr Pharm*, 2011 34, 12, 446-456
15. Allescher, H.D., Weingart, V, **Storr, M.:** Dysphagie – Diagnostik und Therapie. *Kompodium Gastroenterologie* 2011 (3), 4, 84-94.
16. **Storr, M:** Sodbrennen *Arzneimitteltherapie* 30 Heft 11 S 370, 2012
17. **Storr, M:** Update Sodbrennen, So löschen sie den Brand. *Ars Medici* 7, 1-4, 2012
18. **Storr, M:** Der Guanylatcyclaseaktivator Linaclotid ist hilfreich in der Behandlung der chronischen Obstipation *Med. Monatsschr. Pharm.* 35 (7) 261-3, 2012
19. **Storr, M:** Certulizumab Pegol induziert bei Morbus Crohn Patienten mit erhöhtem CRP eine Remission. *Med. Monatsschr. Pharm.* 35 (4) 159-161, 2012
20. **Storr, M:** Zweiwöchige Therapie mit Rifaximin lindert die Symptome bei Reizdarmsyndrom. *Med. Monatsschr. Pharm.* 35 (1) 36-38, 2012
21. **Storr M**, Allescher HD Irritable Bowel Syndrome: A Dysfunction of the Endocannabinoid System? *Gastroenterology*. 2012 Feb;142(2):406-8
22. Allescher HD, **Storr M.:** Irritable Bowel Syndrome a rhinitis of the gut. *Gastroenterology*. Jun;140(7):2132-6; 2136, 2011.
23. **Storr M**, Allescher HD.: Reflux disease as a motility disorder: treatment alternatives to Acid suppression. *Gastroenterology*. 139(6):2207-9, 2010.
24. **Storr, M.:** Functional Gastrointestinal Disorders – New insights in enteric regulation. *Digestive Health Matters*, 3, 2009
25. **Storr, M.:** Evidenz-basierte Phytotherapie bei funktioneller Dyspepsie. *Phytotherapie* 6(3), 31-34, 2006
26. **Storr, M.:** Nicht-kardialer Thoraxschmerz; Motilitätsstörungen; Tabellen zu Endoskopie und Funktionsdiagnostik. In: *Klinikleitfaden der Med. Klinik II*. Hrsg.: B. Göke (2. Auflage), 2006, ISBN: 3-00-017647-0
27. Yüce, B., **Storr, M.:** Rolle des Endocannabinoid-Systems im Gastrointestinaltrakt. In: Schusdziarra, V.: *Das Endocannabinoid-System – Physiologie und klinische Bedeutung*. Seiten 74-87. Uni-Med Verlag, 2006, ISBN: 978-3-89599-987-1
28. Yüce, B., **Storr, M.**, Göke, B.: Alkohol am Gastrointestinaltrakt. *Bayerischer Internist*, 25(5), 224-228, 2005
29. **Storr, M.**, Geisler, F., Neuhuber, W., Allescher, H.D.: Autonomic modulation of vagal input to the rat esophageal muscle – Influence of opiates -*Neurogastroenterology – From*

the Basics to the Clinics. Edited by: H.J.Krammer and M.V. Singer; Kluwer Academic Publishers; Dordrecht, Boston, London, Chapter 8, 71-77, 2000

30. Allescher, H.D., **Storr, M.**: Der Einsatz von Botulinum-Toxin in der Gastroenterologie. Leitlinien der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten für die Durchführung endoskopischer Untersuchungen. 3. Auflage, edited by: T. Sauerbruch and Ch. Scheurlen; Karl Demeter Verlag, Stuttgart, Kapitel 3-II, 95-103, 2002
31. **Storr, M.**, Allescher, H.D.: Motilitäts-modifizierende Pharmaka. Der Internist, 41, 1318–1330, 2000
32. **Storr, M.**, Allescher, H-D.: Back-to-back Koloskopie: Anzahl der in einer Koloskopie übersehenen Adenome. Zeitschrift für Gastroenterologie, 36, 797 – 800, 1998
33. **Storr, M.**: Inhibitorische Mechanismen am Ileum der Ratte, Zelluläre Wirkungsweisen von Neurotensin, ATP, Sin-1 und c-GMP. Dissertationsschrift, 1997

Abstracts

1. Venkatesan, Thangam., Lodhi, Atena., Sengupta, Jyotirmoy., Schroeder, Abigail., Adams, Kathleen., Hogan, Walter J., Wang, Yanzhi., Andrews, Christopher., Storr, Martin.: Marijuana and hot shower use in patients with cyclic vomiting syndrome (CVS), Biology and Control of Nausea and Vomiting, October 3-4, 2013
2. Fichna, J. Sibaev, A., Habibi, S., Bashashati, M., Storr, M.: The GPR30 estrogen receptor controls gastrointestinal cholinergic neurotransmission in the regulation of motility and visceral sensation. UEGW Abstract # 1031, 2013, **Poster of Distinction**
3. Klein, S., Seidler, B., Kettenberger, A., Sibaev, A., Storr, M., Schemann, M., Schmid, R.M., Schneider, G., Saur, D.: Interstitial cells of Cajal integrate excitatory and inhibitory neurotransmission with intestinal slow wave activity. UEGW Abstract # 1031, 2013
4. Storr, M.: Leitliniengerechte Therapie der Reizdarmerkrankung. Jahrestagung der Bayerischen Internisten, Der Bayerische Internist, Oktober 2013.
5. Sibaev A, Abdel-Aziz H, Kelber O, Weiser D, Göke B, Storr M: Inflammation induced acute gastrointestinal hypercontractility is alleviated by STW 5 and its individual herbal components in vitro. DGVS 2013 in Nürnberg. Zeitschrift für Gastroenterologie (xx,xx,2013).
6. Sibaev A, Goeke B., Schirra J., Kapurniotu A, Storr M: Charakterisierung und physiologische Wirkung eines neu-entwickelten löslichen Amylin Analogons in vitro, DGVS 2013 in Nürnberg. Zeitschrift für Gastroenterologie (xx,xx,2013).
7. Sogczak, M., Zyganciewicz, A., Zakrewski, P., J.P. Timmermans, N. Vergnolle, M. Storr, J. Fichna.: Activation of NOP by novel oral available agonist SCH 221510 as new target in the treatment of diarrhoea-predominant IBS. VIII Joint meeting on Medical Chemistry, June 2013 Lublin. Abstractbook p KN-VI
8. Klein, S., Sibaev, A., Storr, M., Sauer, D.: Interstitial cells of Cajal integrate excitatory and inhibitory neurotransmission with intestinal slow wave activity. DDW 2013. Gastroenterology, Vol. 14X, Issue 5, Supplement 1, Pages XXX
9. J. Fichna, S. Habibi, M. Bashashati, M. Storr: GPR30: a novel estrogen receptor which controls gastrointestinal motility and visceral sensation. DDW 2013. Gastroenterology, Vol. 14X, Issue 5, Supplement 1, Pages XXX **Poster of Distinction**
10. Sibaev A, Abdel-Aziz H., Kelber O, Weiser D., Göke B., Storr M.: Entzündungsinduzierte akute gastrointestinale Hyperkontraktilität wird von STW5 und seinen pflanzlichen Einzelkomponenten in vitro gehemmt. Phytokongress 2013, Leipzig, 7.-9.3.2013

11. Y. Nasser, M. Thakrar, D. Helmersen, M. Storr, C. Andrews.: Alterations in esophageal motility post lung-transplantation. NGM Society 2012, Neurogastroenterol. Motil Suppl X 2012.
12. Füllhase C, Campeau L, Sibaev A, Storr M, Gratzke C, Stief C, Hedlund P, Andersson KE: Urological evaluation of a cannabinoid (CB) type 1 receptor knockout mouse; European Urology Society, 2012
13. Sibaev A, Yüce B, Kelber O, Weiser D, Abdel-Aziz H, Göke B, Storr M: Echtzeit in-vitro-Monitoring der Inflammations- induzierten Motilitäts Änderungen und der protektiven Wirkung von Iberogast (STW 5) in einem neu gestalteten Modell. Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V. Februar 2013, Freising
14. Sibaev A, Yüce B, Kelber O, Weiser D., Abdel-Aziz H., Göke B., Storr M.: Antiinflammatorische Wirkung von STW 5 (Iberogast®) auf die durch Entzündungsvorgänge veränderte Motilität und intestinale Neurotransmission in vitro. 67. Jahrestagung der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS). 20.9.2012 Hamburg, Z. Gastroenterol. 50: 9: 896, 2012
15. Füllhase C, Campeau L, Sibaev A, Storr M, Gratzke C, Stief C, Hedlund P, Andersson KE: Neuronal control of micturition via cannabinoid (CB) type 1 receptors - evaluation of a CB1 knockout mouse; American Urology Society, 2012
16. J.Fichna, T. Lapointe, K. Chapman, C. Altier, M.A. Storr: New neostigmine based behavioral mouse model of visceral pain, UEGW 2011, 22-26 October 2011, Stockholm, Sweden, Gut 2011; 60 (Suppl 3) A310
17. Jakub Fichna, Jordyn Stuart, Adam I. Cygankiewicz, Piotr K. Zakrzewski, Anna Mokrowiecka, Maciej Sałaga, Anna Janecka, Ewa Małacka-Panas, Heather B. Bradshaw, Kay Ahn, Martin A. Storr: Inhibition of fatty acid amide hydrolase (FAAH) activity by PF-3845 reduces diarrhoea and alleviates abdominal pain in mice, NGM 2012 Sept 6-8 2012, Bologna Italy, Neurogastroenterol. Mot. 24: 2: 79, 2012
18. Yüce, B., Merz. D., Sibaev, A., Göke, B., Storr, M.: Cannabiniodrezeptor 1 Aktivierung reduziert direkte Kontraktionen der glatten Muskulatur des Ösophagus der Ratte. 57te Jahrestagung der DGVS, 14-17 Sept. 2011 Leipzig; Zeitschr. f. Gastroenterologie 2011, 49: 1091.
19. Sibaev A, Yüce B, Kelber, Weiser D, Göke B, Storr M: Influence of STW 5 and its herbal component extracts on neurotransmission in a model of ileal and colonic inflammation. Joint meeting of the Austrian an German Pharmaceutical societies. 20-23.09.2011, Innsbruck.
20. S Sivapalan, M Storr, T Raedler: The Brain-Gut-Connection in Schizophrenia. Alberta Psychiatric Association. 2011 Scientific Meeting & AGM Rimrock Resort Hotel - Banff, Alberta. March 31 - April 3, 2011
21. A. Sibaev, B. Yüce, O. Kelber, D. Weiser, B. Göke, M. Storr. Wirkungsweise von Iberogast® und seinen Einzelextrakten auf die durch Entzündungsvorgänge veränderte intestinale Neurotransmission. 57te Jahrestagung der DGVS, 14-17 Sept. 2011 Leipzig; Zeitschr. f. Gastroenterologie 2011, 49: 1091.
22. Jakub Fichna, Katarzyna Gach, Renata Perlikowska, Jean-Claude do-Rego, Martin Storr, Anna Janecka: Pharmacological activity of the mu-opioid receptor ligans based on endomorphin-2 and morphiceptin structure in central and peripheral nervous system, European Opioid Conference 2011, Pharmacological Reports, 2011, 63, 248
23. Jakub Fichna, Michael Dickey, Christophe Altier, Kevin Lewellyn, Jordan K. Zjawiony, Wallace K. MacNaughton, Anna Janecka, Martin A. Storr: Kappa opioid and cannabinoid-1 receptors mediate anti-inflammatory and antinociceptive effects of

- salvinorin A on experimental colitis in mice, European Opioid Conference 2011, Pharmacological Reports, 2011, 63, 248
24. Y. Nasser, M. Thakrar, D. Helmersen, M. Storr, C. Andrews.: Gastroesophageal Reflux in pre- and post-transplant patients. CDDW 2011, Can J. Gastroenterol, 2011 Suppl 1.
 25. S. Klein, B. Seidler, F. Nagel, M. Rohn, A. von Werder, M. Schemann, A. Sibaev, M. Storr, R. M. Schmid, G. Schneider, D. Saur Intersitielle Zellen von Cajal (ICC) vermitteln die exzitatorische Neurotransmission in vivo. Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V. 04.-06. March 2011, Freising
 26. Kish, L., Hotte, N., Cheng, E., Rioux, P., Kaplan, G., Vincent, R., Storr, M., Madsen, K: Orally ingested urban particulate matter induces a pro-inflammatory response and decreases microflora diversity. DDW 2011. Gastroenterology, Vol. 140, Issue 5, Supplement 1, Pages S-46-S-47
 27. Quan Samuel, Molodecky Natalie, Frolkis Alex, Proulx Marie-Claude, Lang Eddy, Myers Robert, Storr Martin, Kaplan Gilaad G: Hospitalizations for upper gastrointestinal bleeding secondary to peptic ulcer disease: a population based epidemiological study. DDW 2011. Gastroenterology, Vol. 140, Issue 5, Supplement 1, Page S-730
 28. Alfadda Abdulrahman A., Urbanski Stephan J., Shaffer Eldon A., Storr Martin A.: Eosinophilic Colitis: An Uncommon Self Limited Disease in Middle Aged People without Gender Preference DDW 2011. Gastroenterology,
 29. Stewart, Michael J., Seow, Cynthia H., Storr Martin: Prednisone and budesonide for short and long term treatment of microscopic colitis. A systematic review and meta-analysis. DDW 2011, Gastroenterology Vol. 140, Issue 5, Supplement 1, Page S-31
 30. Syed Atyab, Andrews Christopher, Urbanski Stephan J., Beck Paul, Storr Martin: Rising esophageal biopsy rates are the main confounding factor of increasing incidence of Eosinophilic Esophagitis: a population based study. DDW 2011. Gastroenterology, Vol. 140, Issue 5, Supplement 1, Page S-244
 31. Sivapalan S, Storr M, Raedler T: The Brain-Gut-Connection in Schizophrenia. Alberta Psychiatric Association. 2011 Scientific Meeting & AGM Rimrock Resort Hotel - Banff, Alberta
March 31 - April 3, 2011
 32. Bashashati, M., Keenan, KM., Piomelli, D., Storr, M., Sharkey, KA.: URB937, a peripherally restricted fatty-acid amide hydrolase inhibitor, regulates colonic motility in the mouse: the role of transient receptor potential vanilloid 1 (TRPV1) receptors. Canadian Digestive Disease Week 2011. Can. J. Gastroenterol. 25, Suppl A., 150A, 2011
 33. Stewart M., Andrews, CN., Urbanski, S., Beck, PL., Storr, M.: The association between microscopic colitis and celiac disease. A population based study. Shaffer Award, University of Calgary, May 12, 2011
 34. Syed Atyab, Andrews Christopher, Urbanski Stephan J., Beck Paul, Storr Martin: Rising esophageal biopsy rates are the main confounding factor of increasing incidence of Eosinophilic Esophagitis: a population based study. Shaffer Award, University of Calgary, May 12, 2011
 35. Fichna, J., Saur, D., Timmermanns, JP, Storr, M. Transient receptor potential Type 4 slows motility and reduces epithelial ion transport in the mouse colon. UEGW 23-26.10.2010, Barcelona, Gut, Vol. 59, Suppl III, A-90, 2010
 36. Serum and Urine Metabolic Profiles to Discriminate Crohn's Disease and Ulcerative Colitis. Jennifer Ngo, Hans J. Vogel, Martin Storr. Resident Research Day, University of Calgary, May 10, 2011

37. Andrews, CN., Urbanski, S., Beck, PL., Storr, M.: The association between microscopic colitis and celiac disease. A population based study. Resident Research Day, University of Calgary, May 10, 2011
38. Sibaev, A., Yuce, B., Kelber, O., Storr, M.: Die exzitatorische, cholinerge und inhibitorische, purinerge Neurotransmission wird durch Kaempferol in dem Flavonoid der Iberis Amara im Kolon von Nagern gehemmt. 56te Jahrestagung der DGVS, 15-18 Sept. 2010 Stuttgart; Zeitschr. F. Gastroenterologie 210, 48: 954.
39. Fichna, J., Storr, M.: Transient receptor potential vanilloid type 4 (TRPV 4) in the enteric nervous system. Meeting: The enteric nervous system and intestinal inflammation, Calgary, 5.6.2010
40. M Bashashati, MA Storr, B Lutz, BF Cravatt, KA Sharkey.; Endocannabinoids anandamide and 2-arachidonoylglycerol regulate gastrointestinal contractility in the mouse: the role of fatty acid amide hydrolase (FAAH) and cyclooxygenase (COX)-2. International Meeting of Neurogastroenterology and Motility, 26-29 August 2010, Boston, USA, 2009, Neurogastroenterology and Motility 22, S1, 1-108, 2010
41. Abalo, R., Chen CQ, Vera, G., Castillo, MA., Fichna, J., Thakur, GA., Makriyannis, A., Martin MI., Storr, M.: The cannabinoid agonist AM841 slows GI motility in the rat by peripheral actions. International Meeting of Neurogastroenterology and Motility, 26-29 August 2010, Boston, USA, 2009, Neurogastroenterology and Motility 22, S1, 1-108, 2010
42. Schicho R., Bashashati. M, Saur, D., Zimmer, A., Sharkey, K., Storr, M.: The atypical cannabinoid O-1602 protects against DSS and TNBS induced colitis in mice. International Meeting of Neurogastroenterology and Motility, 26-29 August 2010, Boston, USA, 2009, Neurogastroenterology and Motility 22, S1, 1-108, 2010
43. Fichna, J., Saur, D., Thornloe, K., Timmermanns, JP, Storr, M. Transient receptor potential Type 4 slows motility and reduces epithelial ion transport in the mouse colon. International Meeting of Neurogastroenterology and Motility, 26-29 August 2010, Boston, USA, 2009, Neurogastroenterology and Motility 22, S1, 1-108, 2010
44. Sibaev A., Yuce B., Kelber O., Okpanyi S, Storr M. *Iberis amara L.* and components of it reduce excitatory cholinergic and inhibitory purinergic neurotransmission. 58th International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research, Berlin, 29th August-2nd September, 2010
45. Alfadda, A., Urbanski, S., Shaffer, E., Storr, M.; Clinical features of eosinophilic esophagitis – A report of 7 consecutive cases. DDW New Orleans 2010. Gastroenterology 138 (5), S1, S765, 2010
46. Andrews C., Fraser H., Neshev E., Mintchev, P., Storr M., Bathe, O., Urbanski S.: Full-Thickness Gastric Biopsy: A Novel Percutaneous Endoscopic Transenteric (Peate) Approach in Humans With Gastroparesis. DDW New Orleans 2010. Gastroenterology 138 (5), S1, S1-S906, 2010
47. Sibaev, A., Yuce, B., Kelber, O., Okpani, S., Storr, M.: Iberis amara L and components of it reduce excitatory cholinergic and inhibitory purinergic neurotransmission. Kongress der Society of Medicinal Plant and Natural Products Research (29.08.-02.09.) in Berlin, Germany, Planta Medica 2010
48. Sibaev, A., Yuce, B., Kelber, O., Storr, M.: Kaempferol and Cucurbitacin E Cardinal Constituents of Iberis Amara Reduce Excitatory Cholinergic and Inhibitory Purinergic Neurotransmission in Rodents. DDW New Orleans 2010. Gastroenterology 138 (5), S1, S772, 2010

49. Andrews, C., Syed, A., Urbanski, S., Beck, P., Storr, M.: The rising incidence of Eosinophilic Esophagitis correlates with increased awareness of the disease. DDW New Orleans 2010. *Gastroenterology* 138 (5), S1, S-176, 2010
50. B. Yüce , A. Sibaev , O. Kelber, M., Raab, B., Göke, M., Müller, M., Kreis, M. Storr: Iberogast (STW 5) hemmt die LPS induzierte Hypermotilität der Longitudinalmuskel-schicht des Dünndarms der Ratte in vitro. Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V. 26-28 March 2010, Freising
51. Fraser H., Neshev E., Storr M., Urbanski S., Andrews C.: A novel method of full-thickness gastric biopsy by a percutaneous endoscopic transenteric (PETE) approach. **Poster of Distinction.** Canadian Digestive Disease Week 2010. *Can. J. Gastroenterol.* 24, Suppl A., 153A, 2010
52. Syed, A., Andrews, C., Urbanski, S., Beck, P., Storr, M.: The rising incidence of Eosinophilic Esophagitis correlates with increased awareness of the disease. Canadian Digestive Disease Week 2010. *Can. J. Gastroenterol.* 24, Suppl A., 83A, 2010
53. Alfadda, A., Urbanski, S., Shaffer, E., Storr, M.; Clinical features of eosinophilic esophagitis – A report of 7 consecutive cases. Canadian Digestive Disease Week 2010. *Can. J. Gastroenterol.* 24, Suppl A., 121A, 2010
54. Schicho, R., Bashashti, M., Keenan, C., Mackie, K., Sharkey, K., Storr, M. The GPR55 agonist 0-1602 is protective against DSS colitis via a non-cannabinoid receptor 1 and 2 pathway. *Neuroimmunophysiology of the gastrointestinal tract*, Banff, September 2009.
55. Fichna, M., Storr, M. Salvinorin A reduced intestinal hypermotility and restores neurogenic ion transport in lopolysaccharide-induced endotoxemia in mice. *Neuroimmunophysiology of the gastrointestinal tract*, Banff, September 2009.
56. Storr, M., Nazyrova, A., Ng, J., Bashashati, M., Schneider, C., Beck, P., Shaykhutdinov, R., Vogel, H. Serum metabolic profiles in DWW treated mice identifying potential biomarkers for inflammatory bowel disease. The 5th International Conference of the Metabolomics Society. August 30-September 2, 2009 Edmonton, Alberta, Canada.
57. Yüce, B., Sibaev, A., Kelber, O., Raab, M., Müller, M., Kreis, M., Göke, B., Storr, M.: Kaempferol – ein Flavonoid des Iberis amara extractes (STW 6) und der Gesamtextrakt hemmen elektrisch induzierte Kontraktionen des Ileums und modulieren elektrophysiologische Parameter im proximalen Kolon der Maus. 64. Jahrestagung der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten. DGVS 2009. *Z Gastroenterol* 2009; 47: 9 (Suppl 1).
58. Storr M., Emmerdinger D., Diegelmann D., Pfennig S., Göke B., Ochsenkühn T., Lohse P., Brand S.: The 1359 G/A cannabinoid 1 receptor (CNR1) polymorphism modulates disease susceptibility to ulcerative colitis and CNR1 expression is increased in intestinal inflammation in vivo. 64. Jahrestagung der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten. DGVS 2009. *Z Gastroenterol* 2009; 47: 9 (Suppl 1).
59. Sibaev A., Yuce B., Allescher H.-D., Goeke B., Storr M.: Der ORL-1 (Orphan Opioid Rezeptor 1) reguliert die Ausbreitung myenterischer Signale im Kolon der Maus. 64. Jahrestagung der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten. DGVS 2009. *Z Gastroenterol* 2009; 47: 9 (Suppl 1).
60. Fraser, H., Neshev, E., Storr, M., Urbanski, S., Andrews, C.: A Novel In Vivo Method Of Full-Thickness Gastric Biopsy By A Percutaneous Endoscopic Transenteric (PETE) Approach. 3rd International Meeting of Neurogastroenterology and Motility, 27-30 August 2009, Chicago, USA, 2009, *Neurogastroenterology and Motility* 21, S1, 1-104, 2009
61. Storr, M., Keenan, CM, Thakur, G., Makriyannis, A., Lutz, B., Sharkey, K.: The actions of a novel cannabinoid (CB) receptor agonist AM841 on gastrointestinal (GI) motility in

- mice. 3rd International Meeting of Neurogastroenterology and Motility, 27-30 August 2009, Chicago, USA, 2009, Neurogastroenterology and Motility 21, S1, 1-104, 2009
62. Sibaev, A., Yuce, B., Kelber, O., Raab, M., Goeke, B., Mueller, M., Kreis, M., Storr, M.: Excitatory cholinergic neurotransmission in rodents is modulated by Iberis amara and its major constituents 3rd International Meeting of Neurogastroenterology and Motility, 27-30 August 2009, Chicago, USA, 2009, Neurogastroenterology and Motility 21, S1, 1-104, 2009
 63. Yüce, B., Sibaev, A., Kelber, O., Raab, M., Müller, M., Kreis, M., Göke, B., Storr, M.: Kaempferol – ein Flavonoid des Iberis amara extractes (STW 6) und der gesamtextrakt hemmen elektrisch induzierte Kontraktionen des Ileums und modulieren elektrtophysiologische Parameter im proximalen Kolon der Maus. Berliner Phytotherapietagung, 10-12.9.2009
 64. Sibaev A., Yuce B., Allescher H.-D., Goeke B., Storr M.: Effects of the activations of ORL-1 receptor on spatial spreading of neurotransmission in mouse colon. 3rd International Meeting of Neurogastroenterology and Motility, 27-30 August 2009, Chicago, USA, 2009, Neurogastroenterology and Motility 21, S1, 1-104, 2009
 65. Sibaev, A., Yüce, B., Raab, M., Kelber, O., Göke, B., Storr, M.: STW 6 (Iberis amara-Extrakt), ein Bestandteil von STW 5 (Iberogast[®]) und dessen isolierte Inhaltsstoffe modulieren die cholinerge Neurotransmission im Dünndarm der Ratte MGFG Mitteldeutsche Gesellschaft für Gastroenterologie, Mai 2009
 66. Kaplan, G., Rowe, B., Storr-M Szyszkowicz, M.: Non-Specific Abdominal Pain and Air Pollution: a Novel Association. DDW 2009, 30.May -3.June, Chicago. Gastroenterology, 136, 5 (S1), A162, 2009
 67. Storr, M., Bashashati, M., Vemuri, K., Alapafuja, S., Ho, W., Keenan, CM., Kunos, G., Makriyannis, A., Davison, JS., Sharkey, KA.: Regional Specificity of Fatty Acid Amide Hydrolase (FAAH) Inhibition On Contractility in the Mouse Intestine: Endotoxin Upregulation of FAAH Sensitivity in the Ileum, DDW 2009, 30.May -3.June, Chicago. Gastroenterology, 136, 5 (S1), A719, 2009 - **Poster of Distinction**
 68. Williams, C., Neshev, E., Heitman, S., Storr, M., Cole, M., Andrews, CN.: Peroral Non-Endoscopic BRAVO™ Wireless pH Capsule Insertion Versus Conventional Catheter-Based pH Monitoring: a Prospective, Randomized Trial, DDW 2009, 30.May -3.June, Chicago. Gastroenterology, 136, 5 (S1), A287, 2009
 69. Storr, M., Andrews, CN, Urbanski, S., Dupre, M., Beck, PL.: Detection Bias Influences Increasing Rates of Microscopic Colitis: a Population Based Study, DDW 2009, 30.May -3.June, Chicago. Gastroenterology, 136, 5 (S1), A175, 2009
 70. Yüce, B., Sibaev, A., Kelber, O., Raab, M., Müller, M., Kreis, M., Göke, B., Storr, M.: STW 6 (Iberis amara-Extrakt), ein Bestandteil von STW 5 (Iberogast[®]) und dessen isolierte Inhaltsstoffe modulieren die cholinerge Neurotransmission im Dünndarm der Ratte. Deutsche Gesellschaft für Neurogastroenterologie und Motilität e. V. Jahrestagung 2009, 27.-29. March 2009, Schloss Hohenkammer/Freising.
 71. Papay, K.D., Falck, V.G., Hefeld, J.F., Panaccione, R., Storr, M.: Gigantic Hyperplastic polyposis of the stomach with G cell hyperplasia in a patient with juvenile polyposis syndrome: A case report. CDDW Feb 24-Mar 6, 2009. Banff, Alberta.
 72. Bashashati, M., Storr, M., Vemui, V.K., Lutz, B., Kunos, G., Makriyannis, A., Sharkey, K.A.: Endotoxin treatment causes enhanced sensitivity to fatty acid amide hydrolase (FAAH) inhibition in the gastrointestinal tract. CDDW Feb 24-Mar 6, 2009 Banff, Alberta, Canada.
 73. Williams, C., Neshev, E., Heitman, S., Storr, M., Cole, M., Andrews, C.N.: A prospective randomized trial comparing non-endoscopic unsedated Bravo™ Wireless pH capsule

- insertion versus conventional catheter-based pH monitoring. CDDW Feb 24-Mar 6, 2009 Banff, Alberta, Canada.
74. Sibaev, A., Yüce, B., Raab, M., Kelber, O., Göke, B., Storr, M.: STW 6 (Iberis Amara-Extrakt), eine Bestandteil von Iberogast®, und dessen isolierte Inhaltsstoffe modulieren die Neurotransmission in Nagetieren. Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V. 27-29 March 2009, Schloss Hohenkammer bei Freising
 75. Bashashati, M., Storr, M., Vemuri, V.K., Lutz, B., Kunos, G., Makriyannis, A., Sharkey, K.A.: Endotoxin treatment causes enhanced sensitivity to fatty acid amide hydrolase (FAAH) inhibition in the gastrointestinal tract. GIRG Annual Meeting, Kananaskis, Jan 2009
 76. Williams, C., Neshev, E., Heitman, S., Storr, M., Cole, M., Andrews, C.N.: A prospective randomized trial comparing non-endoscopic unsedated Bravo™ Wireless pH capsule insertion versus conventional catheter-based pH monitoring. GIRG Annual Meeting, Kananaskis, Jan 2009
 77. Davidson, J.S., Bashashati, M., Storr, M., Duncan, M., Keenan, C.M., Vemuri, K., Lutz, B., Mackie, K., Makriyannis, A., Sharkey, K.A.: Endocannabinoids regulate intestinal motility through cannabinoid (CB₁) receptors and fatty acid amide hydrolase in the mouse. *Neurogastroenterol Motil* 2008 (20) Supple 1, 1-144, p 103. **Poster of Distinction**
 78. Yüce, B., Emmerdinger, D., Diegelmann, J., Pfennig, S., Ochsenkühn, T., Göke, B., Lohse, P., Storr, M.; The influence of FAAH (Fatty Acid Hydrolase) expression and FAAH C/A (p.Pro129Thr; rs324420) single nucleotide polymorphism in patients with inflammatory bowel disease. 63. Jahrestagung der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten, Berlin. Oct. 2008. *Z Gastroenterol* 2008; 46: 923-1093.
 79. Yuce, B., Kemmer, M., Sibaev, A., Mueller, M., Kreis, M., Göke, B., Storr, M.; Influence of peripherally active cannabinoid on small intestinal motility in rodents. *Neurogastroenterol Motil.* (20) Supple 1, 114, 2008.
 80. Sibaev, A., Yuce, B., Kemmer, B., Sauer, D., Timmermans, J., Allescher, H., Göke, B., Storr, M.: Regional differences in the effects of the endogenous ORL-1 receptor agonist mociceptin on neurotransmission in mouse colon.. *Neurogastroenterol Motil* (20) Suple 1, 106. 2008
 81. Storr, M., Schäfer, C., Michler, T., Kramer, J., Malo, A., Göke, B.: The role of CB₂-receptors in acute pancreatitis. Annual Meeting of the American-Pancreatic Association 2008.
 82. Kemmer, M., Yüce, B., Sibaev, A., Müller, M., Kreis, M., Göke, B., Storr, M.: Cholinergic transmission in the enteric nervous system is inhibited by the novel peripherally active cannabinoid Ajulemic Acid. Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V. 28-30 March 2008, Schloss Hohenkammer bei Freising
 83. Storr, M., Yuce, B., Wallbach, J., Sibaev, A., Weiser, D., Kelber, O.: Back to the roots? Herbal extracts modulate peristaltic reflex of rat small intestine. CDDW and CASL Winter Meeting Montreal, Quebec, Feb 29-Mar 3, 2008. *Can J Gastroenterol Vol 22 Supple A* Feb 2008.
 84. Storr, M., Keenan, C., Patel, K., Sharkey, K.: The cannabinoid -2 (CB₂) receptor agonist AM1241 mediates protection against TNBS Colitis in mice. *Can J Gastroenterol Vol 22 Suppl A* Feb 2008
 85. Kemmer M., Yuce B., Sibaev A., Muller M., Kreis M., Goke B., Storr M. Cholinergic transmission in the enteric nervous system is inhibited by the novel peripherally active cannabinoid Ajulemic Acid. NGM 2008 Meeting

86. Muller MH., Gong Q, Sibaev A., Vinson B., Weiser D., Kelber O., Storr M., Li Y., Kreis M.: Influence of a herbal fixed combination preparation on intestinal afferent nerve sensitivity in a pharmacological in vivo model. Tagung Phytopharmaka und Phytotherapie, Phytotherapie 28, S31, 2008
87. Storr, M., Yucece B., Wallbach J., Sibaev A., Weiser D., Keiber O.: Back to the roots? Herbal extracts modulate peristaltic reflex of rat small intestine. Tagung Phytopharmaka und Phytotherapie 2008:531 Phytotherapie 28, S31, 2008
88. Kemmer M., Yucece B., Sibaev A., Muller M., Kreis M., Goke B., Storr M. Cholinergic transmission in the enteric nervous system is inhibited by the novel peripherally active cannabinoid Ajulemic Acid. Deutsche Gesellschaft für Neurogastroenterologie und Motilität e. V. Jahrestagung 2008, 28.30. March 2008, Schloss Hohenkammer/Freising.
89. K A. Sharkey, C M. Keenan, H. Zhang, NE. Buckley, B. Lutz, K D. Patel, M A. Storr.: Inhibitors of endocannabinoid degradation reduce colitis by activation of CB₁ and CB₂ receptors. ICERS Meeting 2008, Aviemore, Scotland, 26-29, June.
90. Storr, M., Kramer, J., Michler, T., Malo, A., Goke, B., Schaefer, C.: Acute experimental pancreatitis is ameliorated by activation of cannabinoid-1 (CB1) receptors. DDW 2008, 17-22 May. San Diego. Gastroenterology, 134, 4 (S1), A430, 2009
91. M. Storr, C. Keenan, H. Zhang, K. D. Patel, K. A. Sharkey, Department of Physiology and Biophysics, University of Calgary.: Drugs targeting endocannabinoid degradation protect against experimental colitis in mice. DDW 2008, 17 -22 May, San Diego. Gastroenterology, 134, 4 (S1), A260, 2009 – **Poster of Distinction**
92. I. M. Hons, C. M. Keenan, M. A. Storr, B. Lutz, K. A. Sharkey.: Alterations in synaptic transmission in the enteric nervous system and correlation to motility defects in CB₁ receptor-deficient mice. DDW 2008, 17-22. May, San Diego. Gastroenterology, 134, 4 (S1), A -368, 2008
93. M. Storr, C. Keenan, K. Patel, K. Sharkey.: The cannabinoid-2 receptor agonist AM1241 mediates protection against TNBS colitis in mice. Can. J. Gastroenterology, Vol. 22 Suppl A (75)97A February 2008.
94. M. Storr, B. Yucece, J. Wallbach, A. Sibaev, D. Weiser, O. Kelber.: Back to the roots? Herbal extracts modulate peristaltic reflex of rat small intestine. CDDW 2008, Montreal. Can J Gastroenterology, Vol. 22, Suppl A, (353)181A, Feb 2008.
95. Muller MH., Gong Q, Sibaev A., Kelber O., Vinson B., Weiser D., Storr M., Li Y., Kreis M: Influence of a new Herbal Preparation on Intestinal Afferent Nerve Sensitivity in the Rat In Vivo. 2007 UEGW Meeting, Oct. 2007, Berlin, Germany. GUT 2007
96. Yucece, B., Haaken, A., Sibaev, A., Saur, D., Allescher, H.D. Goke B. Storr, M: Mouse intestinal motility is influence by newly cloned ORL-1 receptor by modulation of cholinergic neurotransmission. 2007 UEGW Meeting, Oct. 2007, Berlin, Germany. GUT 2007
97. C. Schaefer, J. Kramer, A. Malo, B. Goeke, M. Storr.: Flush or new therapeutic options: The role of CB1-receptors in acute experimental pancreatitis. 2007 Annual Meeting of the American-Pancreatic Association, Nov. 2007, Chicago, IL
98. Storr, M., Malo, A., Kramer, J., Göke, B., Schäfer, C.: Rausch oder neuer Therapieansatz: Die Rolle von CB2-Rezeptoren bei der akuten Pankreatitis – Untersuchungen an einem Mausmodell. 62. Tagung der DGVS, 12-15. September 2007, Bochum, Z. Gastroenterol., 45(8), 832, 2007
99. Schäfer, C., Malo, A., Kramer, J., Göke, B., Storr, M.: Rausch oder neuer Therapieansatz: Die Rolle von CB1-Rezeptoren bei der akuten Pankreatitis – Untersuchungen an einem Mausmodell. 62. Tagung der DGVS, 12-15. September 2007, Bochum, Z. Gastroenterol.,

100. Yüce B., Haaken A., Sibaev A., Saur D., Timmermanns J.P., Allescher, H.D., Göke B., Storr M. Modulation der cholinergen Neurotransmission im myenterischen Plexus durch den (opioid-receptor-like) ORL-1 Rezeptor. 35. Kongress der Gesellschaft für Gastroenterologie in Bayern, 25.-27.10.2007 Nürnberg.
101. Storr, M., Keenan, CM., Patel, K., Sharkey, K.: The cannabinoid-2 (CB2) receptor protects against TNBS colitis in mice. CB₂ Cannabinoid Receptors: New Vistas - The first International Conference devoted to studies of the CB₂ cannabinoid receptor. 31.5.-3.6.2007, Banff, Canada
102. Mueller, MH., Gong, Q., Sibaev, A., Kelber, O., Storr, M., Li, YY., Kreis, M.: Intestinal afferent nerve sensitivity to bradykinin is reduced following pretreatment with a new herbal preparation in rat in vitro. DDW 2007, Washington. Gastroenterology, 132(4) Suppl 1, 2007
103. Yuce, B., Sibaev, A., Haaken, A., Saur, D., Goeke, B., Allescher, HD., Storr, M.: Timing and force of the ascending myenteric reflex contraction in rat ileum is modulated by the ORL1 receptor. DDW 2007, Washington. Gastroenterology, 132(4) Suppl 1, 2007
104. Gong, Q., Mueller, M., Sibaev, A., Yuce, B., Li, YY., Storr, M., Kreis, M.: The cannabinoid-1 (CB1) receptor antagonist SR141716A reduces intestinal afferent nerve sensitivity to painful stimuli in mice in vitro. DDW 2007, Washington. Gastroenterology, 132(4) Suppl 1
105. Storr, M., Keenan, CM., Patel, K., Sharkey, K.: The cannabinoid-2 (CB2) receptor protects against TNBS colitis in mice. DDW 2007, Washington. Gastroenterology, 132(4) Suppl 1 **Poster of Distinction**
106. Yüce, B.; Wallbach, J.; Sibaev, A.; Okpany, S.N.; Kelber, O.; Göke, B.; Storr, M.: Wirkung von Pflanzenextrakten auf die Peristaltik des Duennndarms der Ratte. Dt. Pharmakologentagung, Mainz, 14.,03.2007, Arch. Pharmacol, X,XX
107. Gong, Q., Mueller, MH., Sibaev, A., Kelber, O., Li, YY., Storr, M., Kreis, M.E.: Die intestinale afferente Sensibilitaet fuer Bradykinin in vitro ist vermindert nach Gabe der neuen pflanzlichen Praeparation STW5 N-II bei Ratten. Deutsche Gesellschaft für Neurogastroenterologie und Motilität. Hohenkammer 2007
108. Mueller, M.H., Gong, Q., Sibaev, A., Yuce, B., Li, YY., Storr, M., Kreis, M.E.: Der Cannabinoid-1 (CB-1) Antagonist SR141716A reduziert die intestinale afferente Sensibilitaet fuer Schmerzreize bei der Maus in vitro. Deutsche Gesellschaft für Neurogastroenterologie und Motilität. Hohenkammer 2007
109. Yüce, B., Kemmer, M., Sibaev, A., Göke, B., Storr, M.: ALPA, a non-psychoactive cannabinoid inhibits the ascending and the descending part of the peristaltic reflex. Deutsche Gesellschaft für Neurogastroenterologie und Motilität. Hohenkammer 2007
110. Yüce, B.; Wallbach, J.; Sibaev, A.; Schirra, J.; Kelber, O.; Göke, B.; Storr, M.: Iberogast und seine Bestandteile beeinflussen den peristaltischen Reflex am Dünndarm der Ratte. 34. Jahrestagung der Gesellschaft für Gastroenterologie in Bayern, Rosenheim, 26.-28.10.2006. Zeitschrift für Gastroenterologie, 44 (10) P66
111. Beigel, F.; Dambacher, J.; Zitzmann, K.; Storr, M.; Olszak, T.; Goeke, B.; Auernhammer, C. J.; Kaul, A.; Bartenschlager, R.; Diepolder, H.; Brand, S.: The novel Lambda-interferons IL-28A and IL-29 inhibit HCV replication in vitro and hepatic IL-28 mRNA expression is increased in HCV and CMV infection in vivo. 34. Jahrestagung der Gesellschaft für Gastroenterologie in Bayern, Rosenheim, 26.-28.10.2006. Zeitschrift für Gastroenterologie, 44 (10) P45
112. Dambacher, J.; Beigel, F.; Zitzmann, K.; Olszak, T.; Prüfer, T.; Steib, C. J.; Storr, M.; Göke, B.; Diepolder, H.; Bilzer, M.; Auernhammer, C. J.; Brand, S.: IL-22 mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression. 34. Jahrestagung der

- Gesellschaft für Gastroenterologie in Bayern, Rosenheim, 26.-28.10.2006. Zeitschrift für Gastroenterologie, 44 (10) P43
113. Yüce, B.; Haaken, A.; Sibaev, A.; Saur, D.; Timmermans, J. P.; Göke, B.; Storr, M.: Modulation der cholinergen Neurotransmission im Dün- und Dickdarm der Maus und Ratte durch Agonismus am ORL1-Rezeptor. 61. Tagung der DGVS, 13. - 16. September, Hannover, Z. Gastroenterol., 44, V12, 2006
 114. Yüce, B., Wallbach, J., Sibaev, A., Kelber, O., Göke, B., Storr, M. Modulation of the peristaltic reflex of rat ileum segments by STW5. *Phytopharmaka und Phytotherapie 2006*, Berlin Phytotherapie, xx, Sxx, 2006
 115. Yüce, B., Wallbach, J., Sibaev, A., Kelber, O., Schirra, J., Göke, B., Storr, M. Der peristaltische Reflex am Dünndarm der Ratte wird durch Iberogast moduliert. Deutsche Gesellschaft für Innere Medizin, April 2006, Wiesbaden
 116. Sibaev, A., Kelber, O., Weiser, A., Storr, M. Iberogast and its individual herbal components modulate intestinal electrophysiology of mice 10. Int. Congress Phytopharmacology 2006. St. Petersburg.
 117. Sibaev, A., Yüce, B., Storr, M. Pharmacological blockade and genetical ablation of the cannabinoid –1 receptor stimulates peristaltic reflex and gastrointestinal transit. 10. Int. Congress Phytopharmacology 2006. St. Petersburg.
 118. Brand, S., Dambacher, J., Beigl, F., Storr, M., Olszak, T., Zitzmann, K., Göke, B., Auernhammer, C.m Kaul, A., Bartenschlager, R., Diepolder, H. The novel lambda Interferons IL-28A and IL-29 inhibit HCV replication in vitro and hepatic IL-28 mRNA expression is increased in HCV and CMV infection in vivo. DDW 2006, Los Angeles. *Gastroenterology*, 130(4) Suppl 1
 119. Wörle, J., Albrecht, M., Linke, R., Nicolaus, M., Storr, M., Limmer, J., Göke, B., Schirra, J. Gastric emptying, major contributor to postprandial hyperglycemia in patients with type 1 diabetes mellitus. DDW 2006, Los Angeles. *Gastroenterology*, 130(4)Suppl
 120. Sibaev, A., Massa, F., Yüce, B., Marsicano, G., Lehr, H.A., Lutz, B., Göke, B., Allescher, H.D., Storr, M. CB1 and TRPV1 receptors mediate protective effects on colonic electrophysiological properties in mice. DDW 2006, Los Angeles. *Gastroenterology*, 130(4) Suppl 1
 121. Yüce, B., Wallbach, J., Sibaev, A., Kelber, O., Schirra, J., Göke, B., Storr, M. Der peristaltische Reflex am Dünndarm der Ratte wird durch Iberogast moduliert. Mitteldeutsche Gesellschaft für Gastroenterologie, Mai 2006, Chemnitz
 122. Yüce, B., Wallbach, J., Sibaev, A., Kelber, O., Schirra, J., Göke, B., Storr, M. Iberogast und seine Bestandteile beeinflussen den peristaltischen Reflex am Dünndarm der Ratte. Deutsche Gesellschaft für Neurogastroenterologie und Motilität. Hohenkammer 2006
 123. Sibaev, A., Massa, F., Yüce, B., Marsicano, G., Lehr, H.A., Lutz, B., Göke, B., Allescher, H. Storr, M. CB1 and TRPV1 receptors mediate protective effects on electrophysiological properties during colonic inflammation. 33. Jahrestagung der Gesellschaft für Gastroenterologie in Bayern, Amberg, 27.-29.10.2005
 124. Yüce, B., Sibaev, A., Marsicano, G., Lutz, B., Schirra, J., Allescher, H., Göke, B., Storr, M. Pharmacological blockade and genetical ablation of the cannabinoid-1 receptor stimulates peristaltic reflex and gastrointestinal transit. 33. Jahrestagung der Gesellschaft für Gastroenterologie in Bayern, Amberg, 27.-29.10.2005
 125. Sibaev, A., Storr, M., Weiser, D., Kelber, O., Allescher, H.D. The antidyspeptic phytomedicine STW 5 and its components modulate amplitude and frequency of small intestinal slow waves. UEGW Kopenhagen 2005, *GUT*, 54 (10 Suppl.) A 252, 2005
 126. Sibaev, A., Massa, F., Yüce, B., Marsicano, G., Lehr, H.A., Lutz, B., Göke, B., Allescher, H. Storr, M. CB1 and TRPV1 receptors mediate protective effects on electrophysiological

- properties during colonic inflammation.. 60. Tagung der DGVS, 13. - 17. September, Köln Z. Gastroenterol., 43, 811, 2005
127. Sibaev, A., Yüce, B., Kelber, O., Schirra, J., Göke, B., Storr, M. STW5 und seine einzelnen pflanzlichen Extrakte modulieren Elektrophysiologie und Neurotransmission im Gastrointestinaltrakt der Maus. 60. Tagung der DGVS, 13. - 17. September, Köln Z. Gastroenterol., 43, 909, 2005
 128. Wörle, J., Albrecht, M., Linke, R., Nicolaus, M., Storr, M., Limmer, J., Göke, B., Schirra, J. Gastric emptying major contributes for postprandial hyperglycemia in type I diabetes mellitus. 60. Tagung der DGVS, 13. - 17. September, Köln Z. Gastroenterol., 43, 922, 2005
 129. Yüce, B., Sibaev, A., Marsicano, G., Lutz, B., Schirra, J., Allescher, H., Göke, B., Storr, M. Die pharmakologische Blockade und genetische Ablation des Cannabinoid-1 (CB1) Rezeptors stimulieren den myenterischen reflex und den gastrointestinalen Transit. 60. Tagung der DGVS, 13. - 17. September, Köln Z. Gastroenterol., 43, 905, 2005
 130. Massa, F., Sibaev, A., Marsicano, G., Blaudzun, H., Storr, M., Lutz, B. Vanilloid receptor (TRPV-1)-deficient mice show increased susceptibility to dinitrobenzene sulfonic acid induced colitis. 35th Annual Meeting of the Society for Neuroscience, 12.-16.11.05 Program No. 441.16. 2005 Abstract Viewer/Itinerary Planer. Washington DC: Society for Neuroscience, 2005. Online.
 131. Storr, M., Vinson, B., Gundermann, K.H., Weiser D., Allescher, H.D. Evidenz-basierte Phytotherapie bei funktioneller Dyspepsei: Eine systematische Analyse der klinischen Evidenz zu Iberogast. Phytopharmaka und Phytotherapie 7.10.2005, Berlin Phytotherapie, 26, S18, 2005
 132. Sibaev, A., Storr, M., Weised, D., Kelber, O., Allescher, H.D.: The antidyspeptic phytomedicine STW 5 (Iberogast) and its herbal components modulate amplitude and frequency of small intestinal slow waves. 53th Annual Meeting of the Society of Medical Plant Research. 21.-25. 08., Florenz, 2005
 133. Sibaev, A., Yüce, B., Storr, M.: Evidence of changes in functional spreading of neuronal information within the myenteric reflex by cannabinoid-1 receptor activation. International Cannabis Research Society. Leiden 2005
 134. Sibaev, A., Yüce, B., Kelber, O., Weiser, D., Schirra, J., Göke, B., Allescher, H.D., Storr, M.: STW 5 (Iberogast) und seine einzelnen pflanzlichen Extrakte modulieren Elektrophysiologie und Neurotransmission im Gastrointestinaltrakt der Maus. Mitteldeutsche Gesellschaft für Gastroenterologie 5.-7. Mai 2005, Bad Nauheim. **Poster of Distinction**
 135. Lechner, M., J., Nicolaus, M., Storr, M., Göke, B., Schirra: GLP-1 enhances perception of gastric distention independent of its gastric motor effects. DDW, 14-19.Mai, Chicago/USA, 2005 Gastroenterology, 128, 5(Suppl2) A225, 2005
 136. Yüce, B., Sibaev, A., Marsicano, G., Schirra, J., Lutz, B., Allescher, H.D., Göke, B., Storr, M.: Pharmacological blockade and genetical ablation of the cannabinoid-1 receptor stimulates peristaltic reflex and gastrointestinal transit. DDW, 14-19.Mai, Chicago/USA, 2005 Gastroenterology, 128, 5(Suppl2) A607, 2005
 137. Sibaev, A., Yüce, B., Schirra, J., Göke, B., Allescher, H.D., Storr, M.: Evidence of changes in functional spreading of neuronal information within the myenteric reflex by cannabinoid-1 receptor activation. DDW, 14-19.Mai, Chicago/USA, 2005 Gastroenterology, 128, 5(Suppl2) A625, 2005
 138. Sibaev, B. Yüce, J. Schirra, B. Göke, M. Storr: Cannabinoid receptor-1 functioning within the ascending peristaltic reflex. New electrophysiological tools to investigate the spatial

- neuronal projections. Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V. Jahrestagung, Hohenkammer 25.-27.2.2005.
139. Yüce, B., Sibaev, A., Marsicano, G., Schirra, J., Lutz, B., Allescher, H.D., Göke, B., Storr, M.: Pharmacological blockade and genetical ablation of the cannabinoid-1 receptor stimulates peristaltic reflex and gastrointestinal transit. Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V. Jahrestagung, Hohenkammer 25.-27.2.2005.
 140. Lechner, M., Nicolaus, M., Storr, M., Göke, B., Schirra, J. GLP-1 enhances perception of gastric distension independent of its gastric motor effects. Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V. Jahrestagung, Hohenkammer 25.-27.2.2005.
 141. M Lechner, M Nicolaus, M Storr, B Göke, J Schirra.: GLP-1 enhances perception of gastric distention independent of its gastric motor effects. Toulouse, 2004
 142. Storr, M., Weiser, D., Kelber, O., Schirra, J., Allescher, H.D., Sibaev, A.: BACK TO THE ROOTS? Phytopharmaca like STW5 cause changes of small intestinal electrophysiological properties. Gesellschaft für Pharmakologie, Regensburg, 7.-9.10.2004 Z. Gastroenterol., 42, 1220, 2004
 143. Storr, M., Sibaev, A., Weiser, D., Kelber, O., Göke, B., Schirra, J., Allescher, H.D. BACK TO THE ROOTS? Phytopharmaka modulieren Amplitude und Frequenz der "slow-waves" am Dünndarm Gesellschaft für Gastroenterologie in Bayern, Garmisch-Partenkirchen, 28.-30.10.2004
 144. XII. Eur. Symposium on Neurogastroenterology and Motility, September, Cambridge Neurogastroenterology and Motility, 16 (6), 853, 2004
 145. Storr, M., Sibaev, A., Weiser, D., Kelber, O., Göke, B., Schirra, J., Allescher, H.D. Modulation of amplitude and frequency of small intestinal slow waves by different herbal extracts – Motility modifying drugs given by nature
 146. Schirra, J., Nicolaus, M., Struckmeier, C., Storr, M., Göke, B.: Exogenes GLP-1(7-36)amid: Regulation der Freisetzung und Wirkung auf die endokrine Pankreassekretion beim Menschen. 59. Tagung der DGVS, 1. - 4. September, Leipzig Z. Gastroenterol., 42, 786-787, 2004
 147. Lechner, M., Nicolaus, M., Storr, M., Göke, B., Schirra, J.: GLP-1 sensibilisiert für gastrale Dehnungsreize unabhängig von seiner Wirkung auf die gastrale Motorik 59. Tagung der DGVS, 1. - 4. September, Leipzig Z. Gastroenterol., 42, 812, 2004
 148. Frieling, T., Rühl, A., Erckenbrecht, J., Storr, M., et al. Hygiene im Manometrielabor 59. Tagung der DGVS, 1. - 4. September, Leipzig Z. Gastroenterol., 42, 808, 2004
 149. Sibaev, A., Allescher, H.D., Göke, B., Schirra, J., Storr, M.: Are different gap junctions involved in neuromuscular interaction in mouse proximal colon? 59. Tagung der DGVS, 1. - 4. September, Leipzig Z. Gastroenterol., 42, 818, 2004
 150. Storr, M., Sibaev, A., Weiser, D., Kelber, O., Göke, B., Schirra, J., Allescher, H.D.: Das Phytotherapeutikum STW 5 (Iberogast®) und seine Einzelextrakte modulieren Amplitude und Frequenz der "slow-waves" am Dünndarm 59. Tagung der DGVS, 1. - 4. September, Leipzig Z. Gastroenterol., 42, 813, 2004
 151. Storr, M., Sibaev, A., Allescher, H.D.: Are different gap junctions involved in neuromuscular interaction in mouse proximal colon? DDW, 16-21.Mai, New Orleans/USA, 2004 Gastroenterology, 126, 5(1), AXXX, 2004
 152. Storr, M., Sibaev, A., Weiser, D., Kelber, O., Allescher, H.D.: STW 5 (Iberogast®) und seine Einzelextrakte modulieren Amplitude und Frequenz der "slow-waves" am Dünndarm 13. Kongress der Mitteldeutschen Gesellschaft für Gastroenterologie, Suhl, 6.-8. Mai 2004
 153. Storr, M., Sibaev, A., Weiser, D., Kelber, O., Allescher, H.D.: STW 5 (Iberogast®) und seine Einzelextrakte modulieren Amplitude und Frequenz der "slow-waves" am

Dünndarm Gemeinsames Symposium der Deutschen Gesellschaft für Klinische Pharmakologie und Therapie (IX. Symposium), der Gesellschaft für Phytotherapie (14. Kongress) und der Gesellschaft für Arzneipflanzenforschung, Berlin, 26.-28. Februar 2004

154. Kurjak, M., Hamel, A., Saur, D., Storr, M., Allescher, H.D.: Endocannabinoids stimulate release of inhibitory NANC-transmitters – evidence for a functional role of both, a CB2 and a non-CB1, non-CB2 receptor in the ENS. Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V., 08.-09. Februar, Tutzing, 2004
155. Keller, J., Schirra, J., Franke, A., Storr, M., Wiedbrauck, F.: Empfehlungen der Deutschen Gesellschaft für Neurogastroenterologie und Motilität zu Einsatz und Durchführung diagnostisch relevanter Atemtests. Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V., 08.-09. Februar, Tutzing, 2004
156. Sibaev, A., Storr, M., Weiser, D., Kelber, O., Allescher, H.D.: STW 5 (Iberogast®) und seine Einzelextrakte modulieren Amplitude und Frequenz der “slow-waves” am Dünndarm Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V., 08.-09. Februar, Tutzing, 2004
157. Frieling, T., Rühl, A., Wirsing, K., Hagemann, D., Hüttl, T., Keller, J., Kuhlbusch, R., Mönnikes, H., Nordmann, T., Pehl, C., Schirra, J., Storr, M., Vorderholzer, W., Wüst, S.: Hygiene im Manometrielabor: Deutsche Multicenter-Studie (Stand 12/03) Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V., 08.-09. Februar, Tutzing, 2004
158. Massa, F., Marsicano, G., Hermann, H., Cannich, A., Monory, K., Sibaev, A., Storr, M., Cravatt, B., Ferri, G., Lutz, B.: The endogenous cannabinoid system protects against colonic inflammation. 3rd. Int. Symp. on Natural Drugs. 2.-4. 10. 2003, Neapel, Italy.
159. Kurjak, M., Hamel, A., Storr, M., Saur, D., Allescher, H.D.: Der CB2-Rezeptor vermittelt die Stimulation der VIP-Sekretion durch Cannabinoide an Synapsen enterischer Nerven. 58. Tagung der DGVS, 17. - 20. September, Nürnberg Z. Gastroenterol., 41(9), 848, 2003
160. Kurjak, M., Hamel, A., Storr, M., Saur, D., Allescher, H.D.: Anandamid stimuliert die NO Synthese in enterischen Synaptosomen über einen nicht-CB1 / nicht-CB2 –Rezeptor. 58. Tagung der DGVS, 17. - 20. September, Nürnberg Z. Gastroenterol., 41(9), 846, 2003
161. Allescher, H.D., Reichenberger, J., Egger, K., Kurjak, M., Rösch, T., Storr, M.: Endoskopische Antirefluxtherapie mit der Gatekeeper Methode: Prospektive Evaluation von Sicherheit und klinischer Effektivität. 58. Tagung der DGVS, 17. - 20. September, Nürnberg Z. Gastroenterol., 41(9), 870, 2003
162. Kurjak, M., Hamel, A., Storr, M., Saur, D., Allescher, H.D.: Stimulatory role of anandamide n NO synthesis in enteric synaptosomes: Evidence for a non CB1/non CB2 receptor. Int. Neurogastroenterol. Motil. Meeting, Barcelona Neurogastroenterol. Motil., 15 (5), 573, 2003
163. Sibaev, A., Storr, M., Allescher, H.D.: Comparative study of different gap junction blockers on neuromuscular interaction of murine colonic smooth muscle. Int. Neurogastroenterol. Motil. Meeting, Barcelona Neurogastroenterol. Motil., 15 (5), 572, 2003
164. Storr, M., Thammer, J., Dunkel, R., Schusdziarra, V., Allescher, H.D.: Modulatory effect of adenosine receptors on the ascending and descending neural reflexes of rat ileum peristalsis. Mechanismen der Entzündung im Intestinaltrakt: Falk Symposium 133, Berlin, 9.-12. Juni 2003
165. Storr, M., Roesch, T., Born, P., Prinz, C., Kurjak, M., Allescher, H.: Langzeitbehandlung des symptomatischen diffusen Ösophagusspasmus mit Botulinum Toxin. 109. Kongress der Deutschen Gesellschaft für Innere Medizin, Wiesbaden, 2003 Medizinische Klinik, 98 (A1), 95, 2003

166. Storr, M., Sibaeu, A., Marsicano, G., Lutz, B., Allescher, H.: Excitatory cholinergic and inhibitory non-adrenergic, non-cholinergic neurotransmission in murine colon is modulated by the CB1 cannabinoid receptor. Intracellular recording in wild-type and CB1-deficient mice. DDW, 21. Mai, Orlando/USA, 2003 Gastroenterology, 124, 5(1), A116-117, 2003
167. Storr, M., Roesch, T., Born, P., Prinz, C., Kurjak, M., Allescher, H.: Long-term treatment of symptomatic diffuse esophageal spasm by injection of Botulinum Toxin (BTX) DDW, 21. Mai, Orlando/USA, 2003 Gastroenterology, 124, 5(1), A237, 2003
168. Sibaeu, A., Storr, M., Allescher, H.: Comparative study of different gap junction blockers on neuromuscular interaction of murine colonic smooth muscle. Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V., 23.-25. Februar, Tutzing, 2003
169. Storr, M., Sibaeu, A., Marsicano, G., Frank, H., Lutz, B., Allescher, H.D.: Der CB1 Cannabinoid Rezeptor moduliert die Neurotransmission im Kolon der Maus: Untersuchungen an wildtyp und CB1 -/- Mäusen. Deutsche Gesellschaft für Neurogastroenterologie und Motilität e.V., 23.-25. Februar, Tutzing, 2003
170. Lersch, C., Storr, M.: Sonographische Lokalisation eines in den Magen gewanderten Ösophagusstents. 26. Dreiländertreffen der DGUM, Basel, 2002 Ultraschall in Med., 23(Suppl1), S7, 2002
171. Storr, M., Saur, D., Gaffal, E., Schusdziarra, V., Allescher, H.D.: Endomorphine modulieren die intestinale Neurotransmission sowie zeitliche Abläufe des peristaltischen Reflexes über mu-Rezeptoren auf myenterischen Neuronen. XXX Kongress der Gesellschaft für Gastroenterologie in Bayern, Bad Kissingen, 2002 Z. Gastroenterol., 40(9), 844, 2002
172. Storr, M., Haaken, A., Sibaeu, A., Gaffal, E., Schusdziarra, V., Allescher, H.D.: Modulatory role of nociceptin/orphanin FQ and the ORL-1 receptor on cholinergic neurotransmission and the myenteric reflex in rat ileum. XI. Eur. Symposium on Neurogastroenterology and Motility, 2. - 6. Oktober, Tübingen Neurogastroenterology and Motility, 14(5), 573, 2002
173. Sibaeu, A., Marsicano, G., Allescher, H.D., Frank, H., Lutz, B., Storr, M.: CB1 cannabinoidreceptor modulates neurotransmission in mice colon: Intracellular recording in wild-type and CB1-deficient mice. XI. Eur. Symposium on Neurogastroenterology and Motility, 2. - 6. Oktober, Tübingen Neurogastroenterology and Motility, 14(5), 573, 2002
174. Storr, M., Born, P., Rösch, T., Meining, A., Classen, M., Allescher, H.D.: Botulinumtoxin in der Behandlung der Achalasie: Der Erfolg ist unabhängig von einer möglichen Vorbehandlung der Patienten. 57. Tagung der DGVS, 11. - 14. September, Bonn Z. Gastroenterol., 40(8), 703, 2002
175. Tagung der DGVS, 11. - 14. September, Bonn Z. Gastroenterol., 40(8), 631, 2002
176. Storr, M., Sibaeu, A., Marsicano, G., Frank, H., Lutz, B., Allescher, H.D.: Der CB1 Cannabinoidrezeptor moduliert die Neurotransmission im Mäusekolon. Intrazelluläre Aufzeichnungen in Wildtyp und CB1-defizienten Mäusen.
177. Meining, A., Fackler, A., Tzawella, K., Storr, M., Allescher, H.D., Heldwein, W.: Korrelation der stationären Durchzugmanometrie mit dem Tag/Nacht-Profil der 24h-pH-Metrie bei Patienten mit gastro-ösophagealer Refluxkrankheit? 57. Tagung der DGVS, 11. - 14. September, Bonn Z. Gastroenterol., 40(8), 700, 2002
178. Storr, M., Haaken, A., Gaffal, E., Schusdziarra, V., Allescher, H.D.: Nociceptin/Orphanin FQ moduliert die cholinerge Neurotransmission und den myenterischen Reflex des Rattenileum über den ORL1 Rezeptor. 57. Tagung der DGVS, 11. - 14. September, Bonn Z. Gastroenterol., 40(8), 746, 2002

179. Fritsch, R., Storr, M., Geisler, F., Kurjak, M., Berger, H., Rösch, T., Allescher, H.D. Classen, M.: Simultaneous perforation of three major liver blood vessels including lobar hepatic artery and right portal vein by Percutaneous Transhepatic Biliary Drainage. *Intensivmedizin und Notfallmedizin*, 39 (4), 372, 2002
180. Storr, M., Born, P., Weigert, N., Rösch, T., Classen, M., Allescher, H.D.: Response to botulinum toxin injections in achalasia patients is independent of any possible pre-treatment. *AGA, San Francisco/USA, Mai 2002 Gastrointestinal Endoscopy*, 55(5), AB184, 2002
181. Geisler, F., Storr, M., Fritsch, R., Rösch, T., Classen, M., Allescher, H.D.: Endoscopic treatment of a Zenker's diverticulum using argon plasma coagulation in a patient with massive cachexia and esophageal obstruction – a case report and brief review of literature. *XXXII Kongreß der Deutschen Gesellschaft für Endoskopie und bildgebende Verfahren 14.-16. März, München, 2002. Endoskopie heute*, 15(1), 21, 2002
182. Fritsch, R., Storr, M., Geisler, F., Kurjak, M., Berger, H., Rösch, T., Allescher, H.D. Classen, M.: Simultaneous perforation of three major liver blood vessels including lobar hepatic artery and right portal vein by Percutaneous Transhepatic Biliary Drainage. *XXXII Kongreß der Deutschen Gesellschaft für Endoskopie und bildgebende Verfahren 14.-16. März, München, 2002. Endoskopie heute*, 15(1), 21, 2002
183. Storr, M., Born, P., Frimberger, E., Rösch, T., Meining, A., Classen, M., Allescher, H.D.: Botulinum toxin in achalasia patients: response is independent of any kind of pre-treatment. *Achalasia World Congress 2002 Hepatogastroenterology*, 2002
184. Storr, M., Allescher, H.D., Rösch, T., Born, P., Weigert, N., Classen, M.: Treatment of symptomatic diffuse esophageal spasm by endoscopic injection of botulinum toxin: A prospective study with long term follow up. *Gastrointestinal Endoscopy* 54(6), 18A, 2001
185. Storr, M., Koppitz, P., Sibaev, A., Saur, D., Allescher, H.D.: Melatonin moduliert die nitric oxide relaxierende Neurotransmission am enterischen Nervensystem. *XXIX Kongress der Gesellschaft für Gastroenterologie in Bayern, Salzburg, 2001 Z. Gastroenterol.*, 39, 894, 2001
186. Storr, M., Hahn, A., Gaffal, E., Saur, D., Allescher, H.D.: Effects of Endomorphin 1 and 2 on u-opioid receptors in myenteric neurons and in the peristaltic reflex in rat small intestine. *18th Int. Symposium on Gastrointestinal Motility, 11.-15. Nov., Madison, USA Neurogastroenterology and Motility*, 13(4), 371, 2001
187. Koppitz, P., Storr, M., Saur, D., Kurjak, M., Allescher, H.D.: Melatonin moduliert die NO-Antwort am enterischen Nervensystem der Ratte. *DGVS, Münster Z. Gastroenterol.*, 39, 712, 2001
188. Storr, M., Föllmer, R., Kurjak, M., Schusdziarra, V., Allescher, H.D.: Der Protein Phosphatase Inhibitor Okadasäure inhibiert die Neurotransmission am Magenfundus der Ratte. *DGVS, Münster Z. Gastroenterol.*, 39, 715, 2001
189. Lersch, C., Storr, M., Huber, W., Ott, R., Adler, S., Stein, H., Florack, G.: Wegweisender Sonographiebefund: Langstreckige Magenruptur, Spannungs-Pneumo-Peritoneum und Aerobilie nach einer Cardiablutung bei einer Patientin mit Leberzirrhose. *33. Jahrestagung der Deutschen Gesellschaft für internistische Intensivmedizin und Notfallmedizin 20.-23. Juni., Gießen Intensivmedizin und Notfallmedizin*, 38 (4), 326, 2001
190. Huber, W., Storr, M., Saur, D., Werner, M., Siewert, J., Classen, M.: Fulminantes Leberversagen nach laparoskopischer Cholezystektomie. *33. Jahrestagung der Deutschen Gesellschaft für internistische Intensivmedizin und Notfallmedizin 20.-23. Juni., Gießen Intensivmedizin und Notfallmedizin*, 38 (4), 328, 2001

191. Huber, W., Birkenfeld, G., Hennico, R., Steimer, W., Meining, A., Saur, D., Storr, M., Classen, C.: Tödlicher Verlauf einer Pneumocystis carinii Pneumonie bei einem Patienten mit Colitis ulcerosa unter Azathioprin- und Steroid-Therapie. 33. Jahrestagung der Deutschen Gesellschaft für internistische Intensivmedizin und Notfallmedizin 20.-23. Juni., Gießen Intensivmedizin und Notfallmedizin, 38 (4), 369, 2001
192. Huber, W., Eckel, F., Saur, D., Storr, M., Meining, A., Sennefelder, A., Hennico, R., Greiner, L., Porath, J., Schipeck, C., Weiß, W., Classen, M.: Prophylaxe der Kontrastmittel-Nephropathie bei ICU-Patienten: Theophyllin vs. Acetylcystein vs. Theophyllin+Acetylcystein. 33. Jahrestagung der Deutschen Gesellschaft für internistische Intensivmedizin und Notfallmedizin 20.-23. Juni., Gießen Intensivmedizin und Notfallmedizin, 38 (4), 353, 2001
193. Huber, W., Gorgé, L., Eckel, F., Lippl, F., Saur, D., Storr, M., Lersch, C., Classen, M.: Genese, Diagnostik, Therapie und Outcome von 30 Patienten mit akutem Leberversagen. 33. Jahrestagung der Deutschen Gesellschaft für internistische Intensivmedizin und Notfallmedizin 20.-23. Juni., Gießen Intensivmedizin und Notfallmedizin, 38 (4), 328, 2001
194. Storr, M., Fohrer, I., Huber, W., Saur, D., Zimmermann, J., Konstatinow, A., Lersch, C.: Staphylogenes Lyell Syndrom (SSSS) oder Stevens Johnsons Syndrom? 33. Jahrestagung der Deutschen Gesellschaft für internistische Intensivmedizin und Notfallmedizin 20.-23. Juni., Gießen Intensivmedizin und Notfallmedizin, 38 (4), 365, 2001
195. Koppitz, P., Storr, M., Kurjak, M., Allescher, H.D.: Bilirubin reduces the feedback-inhibition of NOS and the NO-release on the enteric nervous system of rat. AGA Atlanta/USA, Mai 2001 Gastroenterology, 120, 5(1), A176, 2001
196. Koppitz, P., Storr, M., Saur, D., Kurjak, M., Allescher, H.D.: Inhibitory effect of melatonin on nitric oxide synthase in rat enteric nervous system. AGA Atlanta/USA, Mai 2001 Gastroenterology, 120, 5(1), A176, 2001
197. Storr, M., Gaffal, E., Saur, D., Schusdziarra, V., Allescher, H.D.: Involvement of cannabinoids in neural transmission in rat gastric fundus. AGA Atlanta/USA, Mai 2001 Gastroenterology, 120, 5(1), A97, 2001
198. Storr, M., Meining, A., Puschmann, A., Allescher, H.D.: Simultane distale ösophageale Kontraktionen – Was ist die zugrundeliegende Erkrankung? 107. Kongress der Deutschen Gesellschaft für Innere Medizin, Wiesbaden, Medizinische Klinik, 96 (A1), 189, 2001
199. Storr, M., Gaffal, E., Saur, D., Allescher, H.D.: Cannabinoid CB₁-Rezeptoren modulieren die Neurotransmission am Magenfundus der Ratte. Arbeitskreis Neurogastroenterologie und Motilität e.V., 4.-6. März, Tutzing, 2001
200. Storr, M., Allescher, H.D., Rösch, T., Born, P., Weigert, N., Puschman, A., Meining, A., Classen, M.: Botulinumtoxin (BTX) in der Langzeitbehandlung des diffusen Ösophagusspasmus. Abstractbook, XXVIII Kongress der Gesellschaft für Gastroenterologie in Bayern, Erlangen, 2000 **Poster of Distinction**
201. Storr, M., Ott, R., Born, P., Frimberger, E., Weigert, N., Kurjak, M., Rösch, T., Classen, M., Allescher, H.D.: Behandlung der Achalasie: Pneumatische Ballondilatation oder Botulinumtoxin Injektion? Abstractbook, XXVIII Kongress der Gesellschaft für Gastroenterologie in Bayern, Erlangen, 2000
202. Allescher, H.D., Storr, M., Ott, R., Born, P., Frimberger, E., Weigert, N., Kurjak, M., Rösch, T., Classen, M.: Treatment of achalasia: pneumatic balloon dilatation versus botulinum toxin injection. 8th United European Gastroenterology Week GUT, 47(Suppl 3), A68, 2000

203. Koppitz, P., Storr, M., Kurjak, M., Allescher, H-D.: Bilirubin reduziert die Autoinhibition der NOS und hemmt die NO Freisetzung am enterischen Nervensystem der Ratte. 55. Tagung der DGVS, 13. - 16. September, Hamburg, Z. Gastroenterol., 38, 740, 2000
204. Storr, M., Gaffal, E., Schusdziarra, V., Allescher, H-D.: Cannabinoide inhibieren die Neurotransmission am Magenfundus der Ratte. 55. Tagung der DGVS, 13. - 16. September, Hamburg, Z. Gastroenterol., 38, 743, 2000
205. Huber, W., Storr, M., Fendt, F., Lersch, C., Schweigart, U., Classen, M.: Fulminantes Leberversagen unter Tuberkulostatika-Therapie. 32. Jahrestagung der Deutschen Gesellschaft für internistische Intensivmedizin und Notfallmedizin 21.-24. Juni., Gießen, Intensivmedizin und Notfallmedizin, 37 (4), 434, 2000
206. Storr, M., Becker, I., Huber, W., Lersch, C., Classen, M.: Septischer Verlauf mit Multiorganversagen einer reaktiv perforierenden Kollagenose durch Superinfektion der Hautläsionen. 32. Jahrestagung der Deutschen Gesellschaft für internistische Intensivmedizin und Notfallmedizin 21.-24. Juni., Gießen, Intensivmedizin und Notfallmedizin, 37 (4), 409, 2000
207. Storr, M., Allescher, H-D., Rösch, T., Born, P., Weigert, N., Classen, M.: Botulinum Toxin (BTX) Injektionen in der Behandlung des symptomatischen Diffusen Ösophagusspasmus. XXX Kongreß der Deutschen Gesellschaft für Endoskopie und bildgebende Verfahren 23.-25. März, Hamburg, 2000 Endoskopie heute, 13(1), 47, 2000
208. Storr, M., Allescher, H-D., Rösch, T., Born, P., Weigert, N., Classen, M.: Behandlung des symptomatischen Diffusen Ösophagusspasmus mit Botulinum Toxin: Eine prospektive Studie mit Langzeit follow.up. Arbeitskreis Neurogastroenterologie und Motilität e.V., 5.-7. März, Tutzing, 2000
209. Storr, M., Geisler, F., Neuhuber, W.L., Schusdziarra, V., Allescher, H-D.: Further evidence against NO involvement in rat esophageal striated muscle innervation. AGA San Diego/USA Gastroenterology, 118, A1199, 2000
210. Storr, M., Allescher, H-D., Rösch, T., Born, P., Weigert, N., Classen, M.: Treatment of symptomatic diffuse esophageal spasm by injection of Botulinum toxin (BTX). AGA San Diego/USA Gastroenterology, 118, A135, 2000
211. Frimberger, E., Zillinger, C., Storr, M., Rösch, T., Jüngst, D., Classen, M.: Laparoscopic cholecystotomy (LCT) with primary closure of the gallbladder for removal of gallbladder stones. AGA Orlando/USA Gastrointest. Endoscopy, 49,4(2), A134, 1999
212. Storr, M., Weigert, N., Weiß, W., Allescher, H-D., Classen, M., Berger, H.: Haemosuccus pancreaticus – eine lebensbedrohliche Komplikation der Pankreatitis. 31. Jahrestagung der Deutschen Gesellschaft für internistische Intensivmedizin und Notfallmedizin 9.-11.Sept., Linz, Österreich Intensivmedizin und Notfallmedizin, 36(6), 578, 1999
213. Storr, M., Schusdziarra, V., Allescher, H-D.: Inhibitory effect of melatonin on smooth muscle cells in the rat gastric fundus – Involvement of small conductance potassium channels. 17th Int. Symposium on Gastrointestinal Motility, 14.-17.Sept., Bruges, Belgium Neurogastroenterology and Motility, 11(4), 293, 1999
214. Storr, M., Geisler, F., Neuhuber, W.L., Allescher, H-D.: Autonomic modulation of vagal input to the rat esophageal muscle - Influence of opiates – 17th Int. Symposium on Gastrointestinal Motility, 14.-17.Sept., Bruges, Belgium Neurogastroenterology and Motility, 11(4), 293, 1999
215. Storr, M., Schusdziarra, V., Allescher, H-D.: Effekt von Melatonin auf die glatte Muskulatur am Magenfundus der Ratte. 54. Tagung der DGVS, 22.-25. September, Leipzig Z. Gastroenterol., 37, 933, 1999
216. Storr, M., Geisler, F., Neuhuber, W.L., Allescher, H-D.: Autonome Modulation des Einflusses des N. vagus auf die Muskulatur des Ösophagus der Ratte – Einfluss von

- Endomorphin 1 und 2 – 54. Tagung der DGVS, 22.-25. September, Leipzig Z. Gastroenterol., 37, 933, 1999
217. Storr, M., Geisler, F., Neuhuber, W.L., Allescher, H-D.: Autonomic modulation of vagal input to the rat esophageal muscle -Influence of opiates -. Falk Symposium 112 (Neurogastroenterology – From the basics to the clinics), 21.-22. Juni, Freiburg, 1999
 218. Storr, M., Franck, H., Schusdziarra, V., Allescher, H-D.: Mechanisms of ATP-induced inhibition in rat ileal smooth muscle: Evidence for a P2x-purinoceptor. Gastroenterology, 116, A1088-1089, 1999
 219. Storr, M., Geisler, F., Neuhuber, W.L., Allescher, H-D.: Characterisation of the autonomic modulation of vagal input to the rat esophageal muscle. Gastroenterology, 116, A1088, 1999
 220. Storr, M., Foellmer, R., Kurjak, M., Schusdziarra, V., Allescher, H-D.: Interaction of inhibitory pathways of NANC relaxation in rat gastric fundus. Gastroenterology, 116, A1088, 1999
 221. Geisler, F., Storr, M., Neuhuber, W.L., Allescher, H-D.: Charakterisierung der autonomen Modulation der vagalen Innervation der Ösophagusmuskulatur an der Ratte. Jahrestagung des Arbeitskreises Gastrointestinale Motilität und Funktion, Tutzing, Februar 1999
 222. Foellmer, R., Storr, M., Allescher, H-D.: Interaktion verschiedener Transmitter bei der inhibitorischen NANC Innervation am Rattenfundus. Jahrestagung des Arbeitskreises Gastrointestinale Motilität und Funktion, Tutzing, Februar 1999
 223. Weigert, N., Storr, M., Weiß, W., Berger, H., Allescher, H-D., Classen, M.: Haemosuccus pancreaticus – eine lebensbedrohliche Komplikation der Pankreatitis. XXIX Kongreß der Deutschen Gesellschaft für Endoskopie und bildgebende Verfahren 3.-6. März, München, 1999 Endoskopie heute, 13 (1), 1999.
 224. Storr, M.: Pharmacological treatment of esophageal dysfunction. European study group for dysphagia and globus. E.G.D.G., Abstractbook, 44-50, 1998.
 225. Huber, A., Storr, M., Trudrung, P., Pfeiffer, A., Ruth, P., Hofmann, F., Allescher, H-D.: Distribution and functional involvement of protein kinase G in the small intestine. AGA Washington/USA Gastroenterology, 112, A751, 1997
 226. Franck, H., Storr, M., Puschmann, A., Allescher, H-D.: Mechanisms of c-GMP-dependent inhibition in rat ileum. 50. Tagung der DGVS, September, Berlin, Z. Gastroenterol, 1995
 227. Franck, H., Storr, M., Puschmann, A., Allescher, H-D.: Cellular mechanisms of the NO-induced inhibition in rat ileum: involvement of intracellular Ca²⁺ stores. AGA San Diego/USA Gastroenterology, 108, A601, 1995
 228. Franck, H., Storr, M., Puschmann, A., Classen, M., Allescher, H-D.: Different involvement of K⁺ channels and intracellular Ca²⁺ stores in the inhibitory action of NANC mediators in rat ileum. 7th European Meeting on Gastrointestinal Motility Toulouse Neurogastroenterology and Motility, 6, 144, 1994
 229. Franck, H., Storr, M., Puschmann, A., Classen, M., Allescher, H-D.: Involvement of K⁺ channels and intracellular Ca²⁺ stores in the inhibitory action of NANC mediators in rat ileum. American Gastroenterological Association New Orleans Gastroenterology, 106, A500, 1994
 230. Franck, H., Storr, M., Puschmann, A., Allescher, H-D., Schusdziarra, V., Classen, M.: Wirkungsmechanismen von inhibitorischen nicht-adrenergen, nicht-cholinergen Transmittern an der Darmmuskulatur. 49. Tagung der DGVS, September, Ulm Z. Gastroenterol., 31, 509, 1994
 231. Franck, H., Puschmann, A., Storr, M., Allescher, H-D., Schusdziarra, V., Classen, M.: Funktioneller Nachweis eines spezifischen Glibenclamid-sensitiven Kaliumkanals im Ileum der Ratte. 100. Tagung der DGIM, 9-13. April, Wiesbaden Med. Klinik, 1994